A Convenient Strategy for the Synthesis of 4,5-Bis(o-haloaryl)isoxazoles

Roberto Olivera,[†] Raul SanMartin,[†] Esther Domínguez,^{*,†} Xabier Solans,[§] Miren Karmele Urtiaga,[‡] and María Isabel Arriortua[‡]

Kimika Organikoa Saila, Zientzi Fakultatea, Euskal Herriko Unibertsitatea, 644 P.K. 48080 Bilbao, Spain, Departmento de Mineralogía y Petrología, Universidad del País Vasco, Apdo 644, 48080 Bilbao, Spain, and Departamento de Cristalografía, Mineralogía y Depósitos Minerales, Universidad de Barcelona, Spain

qopdopee@lg.ehu.es

Received February 26, 2000

A series of new 1,2-bis(o-haloaryl)ethanones is efficiently prepared and applied to the synthesis of 4,5-bis(o-haloaryl)isoxazoles. Isolation of intermediate hydroxyisoxazolines, which are structurally examined, provides a definitive proof for a heterocyclization mechanism based on an amine exchange process. The isolation and X-ray crystallographic studies of significant side products such as benzamides and triarylpropionitriles are also described.

Introduction

Following our research on enaminoketones as precursors of several heterocyclic systems,¹ we planned the preparation of new 4,5-diarylisoxazoles adequately functionalized for a subsequent biaryl coupling reaction which would provide a novel entry to phenanthro-fused isoxazoles. 4,5-Bis(2-haloaryl) isoxazoles (X,Y= Br, I) were chosen as suitable substrates for a final biaryl coupling step, since the commonly used biaryl coupling methodologies are currently carried out with halogenated compounds.²



As an efficient synthesis of 4,5-diaryl-substituted isoxazoles starting from diarylethanones has been already reported,1c a similar protocol could be applied to adequately dihalogenated deoxybenzoins in order to have a ready access to the target halogenated heterocyclic systems. In addition to this synthetic aim, several unknown mechanistic features of the heterocyclization process and some relevant discoveries on the pharmacological properties of isoxazoles³ prompted us to explore this interesting path leading to new 4,5-bis(2-haloaryl)-

isoxazoles. The most outstanding results are presented in this paper.

With regard to deoxybenzoins, since they constitute valuable synthons of a large number of compounds,⁴ several methodologies have been developed for their preparation.⁵ Although the classical Friedel-Crafts acylation of arenes with arylacetyl chlorides is the generally employed strategy,^{5a} nucleophilic substitution of benzyl halides with acyl carbanions has been reported as a versatile alternative.5b

Results and Discussion

1. Synthesis of 2,2'-Dihalodeoxybenzoins. On the basis of the easy preparation of nonhalogenated deoxybenzoins such as 1,⁶ several assays were carried out in order to insert the target halogen substitution at 2,2'positions. In our hands, bromination of deoxybenzoin 1 in both acidic and neutral media only afforded 2-bromo-

^{*} Corresponding author. Tel.: 34 94 6012577. Fax: 34 94 4648500. [†] Kimika Organikoa Saila.

[‡] Departamento de de Mineralogía y Petrología. [§] Departamento de Cristalografía, Mineralogía y Depósitos Minerales.

^{(1) (}a) Domínguez, E.; Mtez. de Marigorta, E.; Olivera, R.; SanMar-(1) (a) Domínguez, E.; Mtez. de Marigorta, E.; Olivera, R.; SanMartin, R. Synlett 1995, 955–956. (b) Olivera, R.; Pascual, S.; Herrero, M.; SanMartin, R.; Domínguez, E. Tetrahedron Lett. 1998, 39, 7155–7158. (c) Domínguez, E.; Ibeas, E.; Mtez. de Marigorta, E.; Palacios, J. K.; SanMartin, R. J. Org. Chem. 1996, 61, 5435–5439.
 (2) (a) Suzuki, H.; Enya, T.; Hisamatsu, Y. Synthesis 1997, 1273–1276. (b) Miyaura, N.; Suzuki, A. Chem. Rev. 1995, 95, 2457–2483.
 (c) Farina, V. Pure Appl. Chem. 1996, 68, 73–78.

⁽³⁾ Several isoxazole derivatives have been reported to exhibit very interesting pharmacological applications, e.g., in the treatment of Alzheimer's disease, as bactericides or as antineoplasic agents. See: (a) Simoni, D.; Manfredini, S.; Tabrizi, M. A.; Bazzanini, P. Ğ.; Baraldi, P. G.; Ferroni, R.; Traniello, F.; Nastruzzi, C.; Feriotto, G.; Gambari, R. Drug. Res. Discov. **1992**, *8*, 165–177. (b) Scobie, M.; Threadgill, M. D. J. Org. Chem. **1994**, *59*, 7009–7013. (c) Diana, G. D.; Rudewicz, P.; Pevear, D. C.; Nitz, T. J. J. Med. Chem. **1995**, *38*, 1355–1371. (d) Shivakumar, B. *Indian J. Heterocycl. Chem.* **1998**, *8*, 27–30. (e) Xue, C. B. *Bioorg. Med. Chem. Lett.*, **1998**, *8*, 3499–3504. The use of isoxazoles as fungicides or herbicides is described in: Hamper, B. C.; Leschinsky, K. L.; Massey, S. S.; Bell, C. L.; Brannigan, L. H.; Prosch, S. D. J. Agric. Food Chem. 1995, 43, 219-228.

^{(4) (}a) Grinshaw, J.; Thompson, N. *J. Chem. Soc., Chem. Commun.* **1987**, *4*, 240–241. (b) Hoyle, C. E.; Cranford, M.; Trapp, M.; No, Y. G.; Kim, K. J. Polymer 1988, 29, 2033-2040. (c) Anstead, G.; Srinivasan, R.; Peterson, C. S.; Wilson, S. R.; Katzenellenboguen, J. A. J. Am. Chem. Soc. 1991, 113, 1378-1385. (d) Mogestern, O.; Richter, P. H.; Ahrens, H. Pharmazie 1992, 47, 25-27.

^{Anrens, H.} *Pharmazie* 1992, 47, 25-27.
(5) (a) Wähäla, K.; Hase, T. A. J. Chem. Soc., Perkin Trans. 1 1991, 3005-3008. (b) Katritzky, A. R.; Oniciu, D. C. Bull. Soc. Chim. Belg. 1996, 105, 635-638. (c) Sato, T.; Narusse, K.; Enokiya, M.; Fujisawa, T. Chem. Lett. 1981, 1135-1136. (d) Ueki, M.; Okamura, A.; Yamaguchi, J.-I. Tetrahedron Lett. 1995, 36, 7467-7470. (e) Miyashita, A.; Matsuoka, Y.; Suzuki, Y.; Iwamoto, K. I.; Higashino, T. Chem. Pharm. Bull. 1997, 45, 1235-1242.
(6) Badia, D.; Carrillo, L.; Dominguez, F.; Cameno, A. G.; Martinez, M. (e) Martinez, M. (e) Martinez, M. (f) Badia, D.; Carrillo, L.; Dominguez, F.; Cameno, A. G.; Martinez, M. (f) Badia, D.; Carrillo, L.; Dominguez, F.; Cameno, A. G.; Martinez, M. (f) Badia, D.; Carrillo, L.; Dominguez, F.; Cameno, A. G.; Martinez, M. (f) Badia, D.; Carrillo, L.; Dominguez, F.; Cameno, A. G.; Martinez, M. (f) Badia, D.; Carrillo, L.; Dominguez, F.; Cameno, A. G.; Martinez, M.; Matsuoka, Y.; Suzuki, Y.; Hartinez, K.; Matsuoka, Y.; Suzuki, Y.; Tukamoto, Y.; Martinez, K.; Matsuoka, Y.; Suzuki, Y.; Tukamoto, K. I.; Higashino, T. Chem. Pharm. Bull. 1997, 45, 1235-1242.

⁽⁶⁾ Badía, D.; Carrillo, L.; Domínguez, E.; Cameno, A. G.; Martinez de Marigorta, E.; Vicente, T. J. Heterocycl. Chem. 1990, 27, 1287-1292.

ethanone **2** (95% yield), whereas iodination of the same ketone **1** with ICl⁷ provided monoiodo derivative **3** with good yield (82%). Attempts to insert the second halogen in **3** with ICl or thallium(III)-mediated iodination⁸ failed, as only traces of 2,2'-diiodo ketone **4** were obtained.

We then assayed Friedel–Crafts acylation of haloarenes with haloarylacetyl chlorides. Despite a previous report,⁹ the reaction between 2-bromo-4,5-dimethoxyphenylacetyl chloride **5a** and bromoveratrole **6a** provided only 25% of the corresponding deoxybenzoin **4**, probably due to a lack of reactivity of derivative **6a**. Similar attempts to prepare diiodo ketone **4** were also unsuccessful, as iodoveratrole **6b** underwent a Lewis acid-promoted dehalogenation.¹⁰ Thus, although iodohomoveratryl chloride **5b** and iodoveratrole **6b** were regioselectively obtained by iodination with ICl, the subsequent Friedel– Crafts acylation step only provided monoiodinated ketone **3** (63% yield).



As Friedel-Crafts strategy failed, the preparation of dihalogenated deoxybenzoins 4 was then attempted by reaction of 2-haloaryl α -aminocarbonitriles 7 with 2-haloarylmethyl chlorides 8. Apart from commercially available 2-bromobenzaldehyde 9a, the preparation of the required 2-haloarenecarbaldehydes 9b-d, synthons of the corresponding α -aminocarbonitriles 7,¹¹ was accomplished as shown in Scheme 1. Oxidation of oiodobenzyl alcohol 10b with activated manganese dioxide and ortho-bromination of veratraldehyde 11 afforded haloaldehydes 9b and 9c, respectively. On the other hand, as iodination of veratraldehyde 11 afforded an inseparable mixture of the 2- and 3-iodoveratraldehydes, the problem was overcome by iodinating veratryl alcohol **12a** with I_2 -CF₃COOAg¹² to **10d** followed by oxidation with pyridinium dichromate to obtain aldehyde 9d. Although the attempts for the aromatic iodination of 12a with ICl unexpectedly afforded iodoveratryl chloride 8d, the latter derivative was readily hydrolyzed to benzyl alcohol 10d. It must be pointed out that $12a \rightarrow 8d$ transformation constitutes a straightforward access to one of the required benzyl chloride precursors 8.13 Finally,



vi: ICI, CHCl3; vii: AgNO3, H2O, MeCOMe

2-bromo-4,5-dimethoxybenzyl chloride **8c** was prepared from **9c** by means of a reduction/chlorination sequence.

The transformation of 2-halobenzaldehydes **9** into the corresponding α -aminonitriles **7** was accomplished by standard procedures (KCN/Me₂NH·HCl),¹¹ though the acetonitrile–water mixture of solvents was preferred to typical methanol in order to avoid acetal formation, thus α -aminonitriles **7a**–**d** were obtained with good yields (Table 1). The next step, the alkylation of derivatives **7** with halobenzyl chlorides **8** provided unexpected results. In fact, as shown in Table 1, it was observed a marked tendency of aminonitriles **7** to undergo oxidation to amides **13** under standard deprotonation conditions (NaH, DMF).¹⁴ In addition, unexpected polyalkylated nitriles **14** were also obtained due to the presence of alkylating chlorides **8**.

This kind of oxidation leading to amides has been rarely observed, and in most cases a bubbling of oxygen through the reaction mixture is required.¹⁵ Therefore, it can be proposed that the *ortho*-halogen substituent activates the benzylic position toward oxidation processes. Taking into account that the captodative effect provoked by amino and cyano functionalities¹⁶ can stabilize a free radical generated by loss of an electron from the α -aminocarbonitrile carbanion, we suggest a mechanism where a peroxide intermediate¹⁷ promotes the formation of amides **13** (Scheme 2).

⁽⁷⁾ Merkusev, E. B. Synthesis 1988, 923-937.

⁽⁸⁾ McKillop, A.; Hunt, J. D.; Zelesku, M. J.; Fowler, J. S.; Taylor, E. C.; McGilliuray, G.; Kienzle, F. J. Am. Chem. Soc. **1971**, *93*, 4841.

^{(9) (}a) Castedo, L.; Iriondo, I.; Domínguez, E.; Lete, E.; Villa, M. J. *An. Quim.* **1985**, *81C*, 61–65. (b) Domínguez, E.; Lete, E.; Iriondo, C.; Villa, M. J. *Bull. Soc. Chim. Belg.* **1984**, *93*, 1099–1103. In our hands, the procedure for the preparation of **5a** reported therein provided only a 25% yield of the target intermediate, probably due to a lack of reproducibility.

⁽¹⁰⁾ Gore, P. H. In *Friedel–Crafts and related reactions*; Olah, G., Ed.; Wiley-Interscience: New York, 1964; Vol. 3, pp 44–46.
(11) (a) Dyke, S. F.; Tiley, S. E.; White, A. C.; Gale, D. P. *Tetrahedron*

^{(11) (}a) Dyke, S. F.; Tiley, S. E.; White, A. C.; Gale, D. P. *Tetrahedron* **1975**, *31*, 1219. (b) Aidhen, I. S.; Narasimham, N. S. *Tetrahedron Lett.* **1991**, *32*, 2171–2174.

⁽¹²⁾ Abelman, M. M.; Overman, L. E.; Tran, V. D. J. Am. Chem. Soc. 1990, 112, 6959–6964.

^{(13) 2-}Bromobenzyl chloride **8a** and 2-iodobenzyl chloride **8b** are commercially available, from Lancaster Co. and Aldrich, respectively. (14) Badía, D.; Domínguez, E.; Iriondo, C. *Bull. Soc. Chim. Belg.*

¹⁹⁸⁶, *95*, 207. (15) Chuang, T.-H.; Yang, C.-C.; Chang, C.-J.; Fang, J.-M. Synlett **1990**, 733–734.

⁽¹⁶⁾ Viehe, H. G.; Janusek, Z.; Merenyl, R.; Stella, L. Acc. Chem. Res. **1985**, *18*, 148–154.

⁽¹⁷⁾ Dibiase, S. A.; Wolak, R. P.; Dishong, D. M.; Gokel, G. W. J. Org. Chem. **1980**, 45, 3630–3634.

Table 1. Aminonitriles 7, Amides 13, and Nitriles 14Prepared



i: KCN, Me₂NH·HCl, MeCN, H₂O; ii: NaH, DMF, 8

R	Х	7 (%)	13 (%)	14 (%)
Н	Br	7a (87)	13a (62)	14a (32)
Н	Ι	7b (85)	13b (65)	14b (31)
OMe	Br	7c (89)	13c (70)	14c (28)
OMe	Ι	7d (89)	13d (55)	14d (41)



Although the autoxidation problem was overcome by means of using degassed DMF, triaryl nitrile derivatives **14** were still obtained as main products (59–72%) along with the expected intermediate enamines **15** (22–31%) when submitting α -aminonitriles **7** to alkylation conditions.

X-ray crystallographic studies accomplished on a monocrystal of nitrile **14a** confirmed the already proposed structure and showed some remarkable structural features of this unexpected byproduct. As shown in Figure 1, there is a clear symmetry plane defined by the *o*-bromoacetonitrile moiety (torsion angles C5-C6-C7-C15 and C1-C6-C7-C15 are 0° and 180°, respectively), and both *o*-bromobenzyl moieties adopt such a conformation that minimizes repulsive interactions between Br substituent, allowing the formation of four C-H···Br and one C-H···N intramolecular hydrogen bonds. Further stabilization is provided by the intermolecular packing



Figure 1. Ortep III view of nitrile **14a** showing the atomic numbering scheme.



Figure 2. Packing diagram of nitrile showing π interactions.

where additional hydrogen bonding and weak $\pi - \pi$ interactions between aromatic rings^{18a-c} form a "zip type" arrangement (Figure 2).^{18d}

To explain the formation of nitriles **14**, it must be considered an initial α -aminonitrile/iminium cyanide equilibrium based on a push-pull type mechanism.¹⁹ In fact, decyanation of α -aminonitriles has been observed in reductive, strongly basic conditions, or mediated by mercury(II) trifluroacetate,²⁰ but not in so high a proportion, probably due to a fast removal of cyanide ion from the equilibrium as it reacts with halobenzyl chlorides **8**. Thus, strongly nucleophilic cyanide ion would replace chloride from halobenzyl derivatives **8** and the so-formed

^{(18) (}a) Nishio, M.; Hirota, M.; Umezawa, Y. in *The CH–Pi Interaction: Evidence, Nature and Consequences*, Marchland, A. P., Ed.; Wiley-VCH: New York, 1998. (b) Hunter, C. A.; Sanders, J. K. M. *J. Am. Chem. Soc.* **1990**, *112*, 5525–5534. (c) The nature and extent of the π - π interactions was evaluated by CONTACTOS program. See: Albert, A.; Cano, F. H. In *Cristalografia*; Hernández-Cano, F., Foces-Foces, C. Martínez-Ripoll, M., Eds.; Publicaciones CSIC: Madrid, 1995; p 183. (d) See Supporting Information for hydrogen bonding and other selected geometric parameters of nitrile **14a**, including π - π interaction parameters.

⁽¹⁹⁾ Ogura, K.; Shimamura, Y.; Fujita, M. J. Org. Chem. **1991**, 56, 2920–2922.

^{(20) (}a) Yamada, S. I.; Akimoto, H. *Tetrahedron Lett.* **1969**, *16*, 3105–3108. (b) Jenning, M. J.; Biles, C.; Romero, D. L. *Tetrahedron Lett.* **1993**, *34*, 4301–4304. (c) Sassaman, M. B. *Tetrahedron* **1996**, *52*, 10835–10840.



arylacetonitriles would undergo an iterative deprotonation/alkylation process to give triaryl nitriles **14** (Scheme 3). The isolation of intermediate **16** (X = Br, R = OMe) provided an additional proof to support our mechanistic proposal.²¹

Finally, enamine derivatives 15a,b were obtained with good yields when α -aminonitriles **7a**,**b** were added onto a mixture of NaH and halobenzyl chlorides 8a,b (method A in Table 2) at -19 °C, as a fast alkylation of 7 avoided the α -aminonitrile/iminium cyanide equilibrium and the subsequent side reactions. However, the same conditions applied to substrates 7c,d and chlorides 8c,d afforded unreacted material and low proportion of the target enamines 15c,d, probably due to a marked instability of the methoxylated benzyl chlorides employed in the presence of NaH.²² To promote a faster alkylation step, halobenzyl bromides 17²³ were assayed as alkylating agents (method B in Table 2), affording enamines 15c,d with good yields. This behavior can be explained considering that, when using bromides 17, a much higher alkylation rate overcomes by far the decomposition rate. Although enamine type intermediates had been proposed by Dyke,^{11a} no diarylenamines such as 15 have been isolated so far. Moreover, strongly acidic conditions and high temperatures (HCl concentrated, 145 °C, 12 h) were required to effect hydrolysis of these halogenated intermediates, although milder conditions (HCl 6 M, 115 °C, 8 h) were enough for some enamines bearing alkoxy substitution.

Table 2. Synthesis of Enamines 15 andDihalodeoxybenzoins 4



^{*a*} Method A: 1. **8**, degassed DMF, NaH, -19 °C, 1 min; 2. **7**, degassed DMF, -19 °C, 10 min \rightarrow rt. ^{*b*} Method B: 1. **7**, degassed DMF, NaH, -19 °C, 60 min; 2. **17**, degassed DMF, -19 °C, 10 min \rightarrow rt. ^{*c*} Overall yield of pure crystallized compound (MeOH). ^{*d*} Hydrolysis was effected by HCl concentrated, 145 °C, 12 h. ^{*e*} Hydrolysis was effected by HCl 6 M, 115 °C, 8 h. ^{*f*} R² + R² = OCH₂O.

2. Spectroscopic Nonequivalence in Vinylogous Amide Systems. As shown in Table 4, enaminoketones 18 were efficiently prepared from diaryl ethanones 4 by treatment with Vilsmeier–Haack type reagent dimethylformamide dimethyl acetal (DMFDMA). Some of the former derivatives 18 showed spectroscopic nonequivalence of the *N*-methyl groups, an effect related to previous observations with nonhalogenated enaminoketones 19a–d.²⁴



In the vinylogous amide system, the contribution of resonance form B causes hindered rotation around C_3 –N. We proposed that depending on the electron-with-drawing nature of the R¹ substituent (alkyl, *p*-methoxy-phenyl, phenyl, and *p*-nitrophenyl) this contribution varies, affecting the rotational barrier for C_3 –N bond which can be observed by ¹H and ¹³C NMR techniques (Figure 3).

However, nonhalogenated 1,2-diarylenaminones **20**, previously prepared by our group,²⁴ showed only one sharp singlet for NMe₂ moiety at room temperature, suggesting that steric factors had to be considered in our theory. As shown in Figure 4, molecular modeling

⁽²¹⁾ In fact, triarylnitriles **14** have been also prepared by addition of sodium cyanide to halogenated benzyl halides in the presence of base. These results will be published elsewhere.

^{(22) &}lt;sup>1</sup>H NMR tecniques showed complete decomposition of methoxylated halobenzyl chlorides **8c**,**d** in the presence of NaH at temperatures above -10 °C. Attempts to carry out the alkylation reaction at lower temperatures afforded enamines **15c**,**d** with moderate yields (40–55%). Although no decomposition product was isolated, the autoalkylation of benzyl chlorides under basic conditions has been reported. See: Hauser; C. R.; Brasen, W. R.; Skell, P. S.; Kantor, S. W.; Brodhay, A. E. *J. Am. Chem. Soc.* **1956**, *78*, 1653–1658.

^{(23) (}a) Iodoarylmethyl bromides **17b** and **17d** were obtained by treatment of alcohols **10b** and **10d** with HBr-H₂O and HBr-CH₃-COOH, respectively. See: Vögtle, N.; Eisen, N.; Franken, S.; Büllesbach, P.; Puff, H. *J. Org. Chem.* **1987**, *52*, 5560–5564. (b) Bromoarylmethyl bromides **17c** and **17e** were prepared by treatment of veratryl alcohol **12a** and homopiperonyl alcohol **12b** with Br₂-CHCl₃, respectively. See: Landais, Y.; Robin, J.-P.; Leburn, A. *Tetrahedron* **1991**, *47*, 3787–3804 and Cochran, J. E.; Padwa, A. *J. Org. Chem.* **1995**, *60*, 3438–3439.

⁽²⁴⁾ SanMartin, R.; Mtez. de Marigorta, E.; Domínguez, E. Tetrahedron 1994, 50, 2255-2264.



Figure 3. ¹H NMR and ¹³C NMR signal shapes corresponding to the NMe₂ moiety of enaminoketones 19 and 20.



🐵 Oxygen; 🖉 Bromo

Figure 4. View of low energy conformations of enaminoketones **20c** and **18a**.

calculations of **20c** ($\mathbb{R}^1 = \mathbb{R}^3 = OMe$, $\mathbb{R}^2 = \mathbb{R}^4 = H$) provided such a low-energy conformation for **20c** where the dimethylamino group, due to the steric interaction with bulky aryl group at C-2, would be located in a perpendicular plane with respect to the latter aryl substituent; thus, the nitrogen lone pair would be almost perpendicular to the enone π orbital system and unable to overlap with it. Therefore, dihaloaryl enaminones **18** would be quite interesting, since according to our calculations the bulky halogen substituent could force the aryl ring to deviate from coplanarity with the enone system, thus allowing resonance with the dimethylamino group and, consequently, spectroscopic nonequivalence of the already mentioned methyl groups attached to nitrogen (Figure 4).

In fact, ¹H NMR spectra of enaminones **18a** and **18c** at room temperature showed for the NMe₂ moiety sig-



Figure 5. ¹H NMR and ¹³C NMR signal shapes corresponding to the NMe₂ moiety of enaminoketone **18a** in DMSO- d_6 at several temperatures.

nificant broad singlets (2.41-2.84 ppm in CDCl₃, 2.39-2.82 ppm in DMSO-*d*₆ for **18a**, 2.59–3.08 ppm in CDCl₃, 2.44–2.91 ppm in DMSO- d_6 for **18c**), and two signals could be found in ¹³C NMR (47.1 and 38.5 ppm in CDCl₃, 47.4 and 38.8 ppm in DMSO-*d*₆ for **18a**, 47.2 and 38.6 ppm in CDCl₃, 46.7 and 37.9 ppm in DMSO- d_6 for **18c**). NMR experiments at different temperatures of enaminoketones 18a and 18c in DMSO-d₆ showed a coalescence temperature of 45 °C and only a sharp singlet in both ¹H and ¹³C NMR spectra at 68 °C (Figure 5). According to the coalescence temperature, the ΔG^{\ddagger} for the rotational barrier has an approximate value of 15.0 kcal/mol. Similar experiments and calculations performed on enaminones **19d** and **20c** provided ΔG^{\ddagger} values of 16.4 and 12.5 kcal/mol, respectively, which is consistent with our proposal based on electronic and steric factors.

3. Synthesis of Dihalogenated Diarylisoxazoles. To obtain the target diarylisoxazoles **21**, enaminoketones **18** were submitted to heterocyclization conditions according to our procedure.^{1c} However, only mixtures of 4,5bis(2-haloaryl)-5-hydroxy-2-isoxazolines **22** and deoxybenzoins **4** were obtained under the latter conditions (Table 3). These results are worth examining, as the



Table 3. Isoxazolines 22 and Ketones 4 from **Enaminoketones 18**



i: NH₂OH·HCI, AcOH, K₂CO₃, MeOH-H₂O, ↑↓, 11h

R	Х	22 (%)	4 (%)
Н	Br	22a (58, $36/64^a$)	4a (37) 4b (21)
OMe	Br	220 (61, 22/78 ^a) 22c (66, $46/54^a$)	4D (31) 4c (29)
OMe	Ι	22d (60, 44/56 ^a)	4d (35)

^a Cis/trans ratio, calculated from the relative integration of the ¹H NMR signals (m) corresponding to H-4.

isolation of hydroxyisoxazolines 22 provides a valuable proof of an amine exchange-based mechanism,¹ and the formation of deoxybenzoins illustrates an unusual process in the chemistry of enaminoketones.

With regard to hydroxyisoxazoline intermediates 22ad, which were obtained as mixtures of *cis/trans* diastereoisomers, their lack of reactivity toward dehydration might be the reason for their isolation. The structure of these isoxazolines 22, confirmed by X-ray diffraction techniques performed on a monocrystal of the trans- $4S^*, 5S^*$ -isomer of **22b** (owing to the $P2_1/c$ space-group centrosymmetry, both the *R*.*R* and *S*.*S* enantiomers are present in the crystal and only the S,S-configuration is represented in Figure 6), showed the isoxazoline ring in an almost ideal envelope-type conformation (puckering parameters Q, θ , and φ^{25} are 0.262–0.267, n/c, and 323.4-328.4°, respectively).

On the other hand, the formation of deoxybenzoins 4 from enaminoketones 18 illustrates an unusual behavior of enaminoketones related to a retro-Mannich reaction. We propose that enaminones 18 could undergo a conjugate addition of water leading to an adduct which eliminates DMF, giving rise to ketones 4 (Scheme 4). In fact, DMF was isolated along with derivatives 4 from the reaction mixture.²⁶



Figure 6. PLATON view of hydroxyisoxazoline 22b. The asymmetric unit is composed of two slightly different conformers of the same molecule.

The formation of deoxybenzoins 4 was avoided by sonication of the reaction mixture at 65 °C, consequently the yield of hydroxyisoxazolines 22 was much improved (78-84%). However, the target isoxazoles 21 could not be obtained by simple heating, sonication, or treatment under acidic (p-TsOH, H₂SO₄ aq) or basic (K₂CO₃, NaOAc, or pyridine) conditions to effect dehydration of derivatives 22. A related behavior has already been reported by Anjaneyulu et al.27 This problem was sorted out by performing the reaction in a heavy wall pressure tube. The effect of working at higher temperatures than the boiling point of the solvent and higher pressures than the atmospheric²⁸ was crucial, as target isoxazoles 21 were regioselectively obtained in short reaction times (1.5-2.0 h). Table 4 shows the results obtained for the synthesis of these bis(haloaryl) heterocycles 21 along with their precursors 18.

In addition to the observed regioselectivity of the heterocyclization reaction, the isolation of intermediates 22 rules out the possibility of a mechanism based on a hydroxylamine attack to form the corresponding oxime A whose hydroxy group would displace dimethylamino moiety. Therefore, our mechanistic proposal,^{1c} based on an initial amine-exchange process followed by nucleophilic addition of hydroxylamine derivative B to the carbonyl group and dehydration, is clearly confirmed (Scheme 5).

To sum up, an efficient strategy for the preparation of o,o'-dihaloarylethanones is reported. This methodology overcomes a number of synthetic problems associated to the presence of the o,o'-dihalo substituents, presenting

⁽²⁵⁾ Cremer, D.; Pople, J. A. J. Am. Chem. Soc. 1975, 97, 1354-1358

⁽²⁶⁾ See Experimental Section for more details. An alternative mechanism based on the hydrolysis of 18 to the aldehyde followed by oxidation to the corresponding keto-acid and subsequent decarboxylation was discarded as it could not explain the formation of DMF.

⁽²⁷⁾ Anjaneyulu, A. S. R.; Rani, G. S.; Mallavadhani, U. V.; Murthy, Y. L. N. Indian J. Heterocycl. Chem. 1995, 4, 277–280. (28) Isaacs, N. S. Tetrahedron 1991, 47, 8463–8497.

Table 4. Synthesis of Dihaloaryl Enaminones 18 and
Isoxazoles 21



i: DMFDMA, toluene, ↑↓

ii: NH2OH·HCI, AcOH, K2CO3, ROH (R= Me, ⁱPr),

	115°C, sealed				
\mathbb{R}^1	\mathbb{R}^2	X^1	X ²	18 (%) ^a	21 (%) ^a
Н	Н	Br	Br	18a (77)	21a (92)
Н	Н	Ι	Ι	18b (78)	21b (90)
OMe	OMe	Br	Br	18c (75)	21c (89)
OMe	OMe	Ι	Ι	18d (70)	21d (98) ^b
OMe	Н	Br	Br	18e (79)	21e (91)
OMe	Н	Ι	Ι	18f (71)	21f (89) ^b
Н	OMe	Br	Br	18g (81)	21g (92)
Н	OMe	Ι	Ι	18h (86)	21h (88)
Н	OMe	Br	Ι	18i (82)	21i (81)
Н	OMe	Ι	Br	18j (77)	21j (78)
Н	OCH_2O^c	Br	Br	18k (84)	21k (93)

^{*a*} Yield of pure crystallized compound (MeOH). ^{*b*} The reaction was performed using ^{*i*}PrOH as solvent. MeOH was the solvent of choice in the synthesis of the rest of isoxazoles **21**. ^{*c*} $R^2 + R^2 = OCH_2O$.

Scheme 5



at the same time interesting side products and significant intermediates, such as triarylpropionitriles, benzamides, deoxybenzoins, and 5-hydroxyisoxazolines. In addition, X-ray structural examination of some of the latter compounds and a general explanation for the spectroscopic behavior of enaminoketones based on electronic/ conformational factors are also reported.

Experimental Section

General. For general experimental details, see ref 1c. MM2 parameters²⁹ were applied by MOLGEN³⁰ and CSChem3D³¹ programs to perform conformational calculations. The data

collection and cell refinement of crystallographic analysis were performed by CAD-4 software.³² The crystallographic data reduction was carried out by Xtal3.2,³³ and the structure was solved by SHELXL86 and refined by SHELXL93 programs.³⁴

Preparation of Chloride, Bromide, and Aldehyde Precursors.

2-Iodobenzaldehyde (9b). MnO₂ (82.5 g, 0.854 mol) was added in little portions to a stirred solution of alcohol **10b** (10 g, 42.7 mmol) in chloroform (200 mL) at room temperature. After stirring for 1 h, the mixture was filtered, and the filtrate was evaporated in vacuo to provide a colorless oil which was crystallized from hexane. 2-Iodobenzaldehyde **9b** (9.0 g, 91%) was obtained as a brown powder: mp 37–38 °C (hexane) (lit.³⁵ 37 °C (hexane)); R_f 0.54 (5% EtOAc/hexane); ¹H NMR (CDCl₃) δ 7.26 (1H, ddd, J = 7.5, 7.5, 1.9 Hz), 7.46 (1H, ddd, J = 7.5, 7.5, 1.9 Hz), 7.85 (1H, dd, J = 7.5, 1.9), 7.93 (1H, dd, J = 7.5, 1.9 Hz) 10.04 (1H, s); ¹³C NMR (CDCl₃) δ 101.2, 128.6, 130.1, 134.6, 135.2, 140.5 195.1; FTIR (neat film, cm⁻¹): 1693; EIMS (m/z, %) 232 (M⁺, 100), 104 (71).

2-Bromo-4,5-dimethoxybenzaldehyde (9c). Typical Procedure. A solution of bromine (3.2 mL, 62.5 mmol) in dry chloroform (8 mL) was added dropwise to a stirred solution of veratraldehyde (10.0 g, 60.1 mmol) in dry chloroform (80 mL) under argon at room temperature. The mixture was heated to 60 °C for 6 h, and after cooling, it was concentrated in vacuo. The residue was washed with chloroform and evaporated under reduced pressure. Crystallization from MeOH afforded bromoveratraldehyde **9c** (13.1 g, 89%) as a white powder: mp 147–148 °C (MeOH) (lit.³⁶ 149–151 °C (MeOH)); R_f 0.54 (3% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.92 (3H, s), 3.96 (3H, s), 7.06 (1H, s), 7.42 (1H, s) 10.19 (1H, s); ¹³C NMR (CDCl₃) δ 55.9, 56.3, 110.2, 115.3, 120.2, 126.3, 148.7, 154.3 190.5; FTIR (neat film, cm⁻¹): 1669; EIMS (*m*/*z*, %) 246 (M + 1, 94), 244 (M - 1, 100), 231 (16), 229 (18).

The same procedure applied to (3,4-dimethoxyphenyl)methanol **12a** afforded (2-bromo-3,4-dimethoxyphenyl)methyl bromide **17c** (91%) as a white powder: mp 118–119 °C (hexane) (lit.³⁷ 121–123 °C (cyclohexane))

The same procedure applied to 5-(hydroxymethyl)-1,3benzodioxole **12b** afforded 5-bromo-6-(bromomethyl)-1,3-benzodioxole **17e** (93%) as a white powder: mp 88–90 °C (Et₂O) (lit.³⁸ 92–93 °C (MeOH))

(4,5-Dimethoxy-2-iodophenyl)methyl Chloride (8d). A solution of ICl (5.44 g, 32.8 mmol) in dry CHCl₃ (15 mL) was added to a stirred solution of veratryl alcohol (4.61 g, 27.4 mmol) in dry CHCl₃ (75 mL) under argon at room temperature. After stirring for 2 h, water (400 mL) and Na₂S₂O₅ were added until the purple iodine color was discharged. After decantation, the organic layer was washed with saturated aqueous Na₂S₂O₅, dried over anhydrous sodium sulfate, and evaporated in vacuo. Crystallization of the residue from 15% EtOAc/hexane afforded iodo derivate **8d** (4.79 g, 56%) as a red powder: mp 80–81 °C (Et₂O) (lit.³⁹ 84–85 °C (MeOH)).

- (29) (a) Podogar, B. L.; Raber, D. J. J. Org. Chem. 1989, 54, 5032–5035.
 (b) Allinger, N. L. J. Comput. Chem. 1993, 14, 755–768.
- (30) Baricic, P.; Mackov, M.; Slone, J. E., MOLGEN 4.0, 1996, SCSI, Alexandria, VA.
- (31) Chem3D Pro 3.5.2, 1997, CambridgeSoft Corporation, Cambridge, MA.
- (32) Enraf-Nonius *CAD-4 Software 5.0*, Enraf-Nonius, Delft, The Netherlands.
- (33) Hall, S. R.; Flack, H. D.; Stewart, J. M. *XTal3.2 Reference Manual*; Universities of Western Australia, Australia, Geneva, Switzerland, and Maryland.

(34) (a) Sheldrick, G. M. *Acta Crystallogr.* **1990**, *A46*, 467–473. (b) Sheldrick, G. M. *SHELXL93. Program for the refinement of crystal structures*, 1993, University of Göttingen, Germany.

(35) (a) Smith, W. B.; Deavenport, D. L.; Ihrig, A. M, J. Am. Chem. Soc. **1972**, 94, 1959–1965. (b) Dictionary of organic compounds; Buckingham, J.; Donoghy, S. M., Ed.; Chapman & Hall: Easton, Pennsylvania, 1982; Vol. 3, p 3222.

(36) Dictionary of organic compounds, Buckingham, J.; Donoghy,
 S. M. Ed.; Chapman & Hall: Easton, Pennsylvania, 1982; Vol 5, p 786.
 (77) Sharar T. Harraruki, H.: Scachi, M.: Ewitte, S. Marcari, K.

(37) Shono, T.; Hamaguchi, H.; Sasaki, M.; Fujita, S.; Nagami, K. J. Org. Chem. **1983**, *48*, 1621–1628.

(38) Barthel; W. F.; Alexander, B. H. *J. Org. Chem.* **1958**, *28*, 1012–1014.

4,5-Dimethoxy-2-iodophenylmethanol (10d). A solution of iodine (18.2 g, 70.4 mmol) in dry CHCl₃ (50 mL) was added to a stirred solution of veratryl alcohol 12a (9.8 g, 58.7 mmol) and silver trifluoroacetate (14.1 g, 64.6 mmol) in dry CHCl₃ (250 mL) under argon at room temperature. After stirring for 2 h, the mixture was filtered, and the filtrate was concentrated under reduced pressure, giving a yellow oil which was triturated with Et_2O to afford alcohol **10d** (15.7 g, 91%) as a yellow powder: mp 96-97 °C (Et₂O) (lit.³⁹ 77-78 °C (Et₂O))

An alternative procedure for the preparation of 4,5dimethoxy-2-iodophenylmethanol 10d is described below:

A solution of chloride 8d (6.43 g, 206 mmol) in acetone (15 mL) was added dropwise to a stirred suspension of AgNO₃ (3.64 g, 212 mmol) in acetone (50 mL) and water (50 mL) at room temperature. After being stirred for 1 h, the mixture was filtered, and the filtrate was washed with CH₂Cl₂. The filtrate was concentrated under reduced pressure, and the residue was triturated with Et₂O to provide alcohol **10d** (6.0 g, 99%) as a white powder.

2-Bromo-4,5-dimethoxyphenylmethanol (10c). NaBH₄ (1.66 g, 44 mmol) was added in little portions to a stirred solution of aldehyde 9c (10.8 g, 44 mmol) in dry MeOH (27 mL) and dry CHCl₃ (13 mL) at 0 °C under argon. After stirring at the same temperature for 1 h, water (400 mL) was added, and the aqueous layer was extracted with $CHCl_3$ (3 \times 70 mL). The combined organic layers were dried over anhydrous sodium sulfate and evaporated in vacuo to give a residue which was crystallized from Et₂O. Alcohol 10c (8.0 g, 74%) was obtained as a white powder: mp 91–93 °C (Et₂O) (lit.⁴⁰ 82.5 °C); $R_f 0.15$ (5% EtOAc/CHCl₂); ¹H NMR (CDCl₃) δ 3.69 (3H, s), 3.70 (3H, s), 4.48 (2H, s), 6.82 (1H, s) 6.85 (1H, s); ¹³C NMR (CDCl₃) & 55.3, 55.7, 63.8, 110.6, 111.1, 114.1, 131.6, 147,9, 148.2; FTIR (neat film, cm⁻¹): 3388; EIMS (m/z, %) 249 (M + 2, 9), 248 (M + 1, 76), 247 (M⁺, 13), 246 (M - 1, 16), 231 (18), 229 (10), 167 (29), 139 (100).

2-Bromo-4,5-dimethoxyphenylmethyl Chloride (8c). Me₂S (1.14 mL, 14.6 mmol) was added to a stirred suspension of NCS (1.83 g, 13.4 mmol) in dry CH_2Cl_2 (70 mL) at -25 °C under argon. After the mixture was stirred at the same temperature for 15 min, a solution of alcohol 10c (3.0 g, 12.1 mmol) in dry CH₂Cl₂ (5 mL) was added, and the resulting suspension was allowed to warm to 0 °C. The stirring at 0 °C was continued for 2 h, and then the reaction mixture was poured onto an ice-water mixture (20 mL). The aqueous layer was extracted with Et₂O (3 \times 50 mL), and the combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, and evaporated in vacuo. The resulting yellow oil was purified by flash chromatography using 10% EtOAc/hexane as eluent, affording chloride 8c (2.64 g, 82%) as a white powder: mp 60-61 °C (20% hexane/Et₂O); (lit.⁴¹ 55 °C (CCl4); R_f 0.91 (hexane); ¹H NMR (CDCl₃) δ 3.81 (3H, s), 3.82 (3H, s), 4.60 (2H, s), 6.85 (1H, s) 6.97 (1H, s); ¹³C NMR (CDCl₃) δ 46.3, 55.8, 55.9, 113.0, 114.3, 115.3, 128.3, 148.3, 148.5; FTIR (neat film, cm⁻¹): 1440 (CH₂); EIMS (*m*/*z*, %) 266 (M + 1, 25), 264 (M - 1, 19), 231 (100), 229 (94).

4,5-Dimethoxy-2-iodobenzaldehyde (9d). A solution of alcohol 10d (10 g, 34 mmol) in dry CH₂Cl₂ (20 mL) was added to a stirred suspension of PDC 17 (20.1 g, 51 mmol) in dry CH $_{2}\text{-}$ Cl₂ (300 mL) under argon at 0 °C. After stirring for 45 min at the same temperature, Et₂O (200 mL) was added, the mixture was filtered, the filtrand was repeatedly washed with Et₂O. The combined organic layers were concentrated in vacuo to give aldehyde 9d (9.43 g, 95%) as a white powder: mp 115-117 °C (Et₂O) (lit.³⁹ 85–95 °C (dec) (CHCl₃)) $R_f 0.33$ (CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.90 (3H, s), 3.94 (3H, s), 7.29 (1H, s), 7.40 (1H, s) 9.85 (1H, s); ¹³C NMR (CDCl₃) δ 56.0, 56.4, 92.7, 111.0, 121.7, 128.3, 149.7, 154.4 194.8; FTIR (neat film, cm⁻¹): 1670; EIMS (m/z, %) 292 (M⁺, 100), 164 (11).

(4,5-Dimethoxy-2-iodophenyl)methyl Bromide (17d). A solution of alcohol 10d (15.0 g, 51.0 mmol) in dry CH₂Cl₂ (45 J. Org. Chem., Vol. 65, No. 20, 2000 6405

mL) was added slowly to a stirred solution of HBr (120 mL, 47% in water) under argon at 0 °C. After being stirred for 1 h, the mixture was allowed to warm, and it was diluted with water (500 mL). The aqueous layer was extracted with CH₂- Cl_2 (3 \times 100 mL), and the combined organic layers were washed with saturated aqueous NaHCO₃, dried over anhydrous sodium sulfate, and evaporated in vacuo. The resulting red oil was purified by flash chromatography using 20% EtOAc/hexane as eluent, providing bromide 17d (16.2 g, 89%) as a white powder: mp 89-90 °C (Et₂O); R_f 0.36 (15% EtOAc/ hexane); ¹Ĥ NMR (CDCl₃) & 3.82 (3H, s), 3.83 (3H, s), 4.53 (2H, s), 6.92 (1H, s) 7.18 (1H, s); ¹³C NMR (CDCl₃) & 39.3, 55.5, 55.7, 88.3, 112.3, 121.1, 131.8, 148.8, 148.9; FTIR (neat film, cm⁻¹): 1452; EIMS (m/z, %) 358 (M + 1, 10), 356 (M - 1, 10), 277 (100).

(2-Iodophenyl)methyl Bromide (17b). A solution of HBr (105 mL, 33% in AcOH) was added to a stirred solution of 2-iodobenzyl alcohol 10b (10.5 g, 44.4 mmol) in AcOH (5 mL) under argon at 0 °C. After the mixture was stirred at the same temperature for 45 min, water (600 mL) was added, and the resulting white precipitate was filtered and redissolved in CH2-Cl₂ (100 mL). This organic layer was washed with saturated aqueous NaHCO₃ and water, dried over anhydrous sodium sulfate, and evaporated in vacuo. The residue was crystallized from MeOH to provide 2-iodobenzyl bromide 17b (12.4 g, 95%) as a white powder: mp 48-50 °C (MeOH), (lit.42 56-57 °C (Et₂O)); $R_f 0.76$ (20% EtOAc/hexane); ¹H NMR (CDCl₃) δ 4.60 (2H, s), 6.99 (1H, ddd, J = 7.7, 7.7, 1.7 Hz), 7.33 (1H, ddd, J)J = 7.5, 7.5, 1.0 Hz), 7.47 (1H, dd, J = 7.7, 1.7 Hz) 7.85 (1H, dd, J = 7.5, 1.0 Hz); ¹³C NMR (CDCl₃) δ 38.8, 100.0, 128.8, 130.0, 130.4, 139.9, 140.0; FTIR (neat film, cm⁻¹): 1463; EIMS (m/z, %) 298 (M + 1, 12), 296 (M - 1, 12), 217 (100).

Synthesis of Aminonitriles.

2-(2-Bromo-4,5-dimethoxyphenyl)-2-(N,N-dimethylamino)acetonitrile (7c). Typical Procedure. Veratraldehyde 11 (5.14 g, 21.0 mmol) was dissolved in CH₃CN (85 mL), and the resulting solution was added dropwise to a stirred solution of NaCN (1.72 g, 34.4 mmol) and Me₂N·HCl (4.78 g, 58.0 mmol) in water (34 mL) at room temperature. After stirring for 18 h, the reaction mixture was concentrated in vacuo, and the residue was redissolved in water (150 mL) and extracted with diethyl ether (4 \times 75 mL). The combined organic layers were washed with saturated aqueous NaHCO $_3$ (3×50 mL), water (50 mL), and brine (50 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was crystallized from methanol to afford α -aminonitrile 7c (5.59 g, 89%) as a yellow powder: mp 72–73 °C (MeOH); R_f 0.39 (5% EtOAc/CH₂Cl₂); ¹Ĥ NMR (CDCl₃) δ 2.33 (6H, s, NMe), 3.86 (3H, s), 3.89 (3H, s), 4.95 (1H, s), 7.04 (1H, s), 7.05 (1H, s); $^{13}\mathrm{C}$ NMR (CDCl_3) δ 241.6, 56.2, 62.2, 104.7, 112.4, 114.9, 115.1, 116.1, 148.1, 149.9; FTIR (neat film, cm⁻¹): 2230; EIMS (m/z, %) 300 (M + 1, 9), 298 (M - 1, 9), 257 (13), 255 (13), 254 (100). Anal. Calcd for $C_{12}H_{15}BrN_2O_2$: C, 48.18; H, 5.05; N. 9.36. Found: C, 48.29; H, 5.11; N, 9.47.

By use of the same procedure, the following compounds were prepared:

2-(2-Bromophenyl)-2-(N,N-dimethylamino)acetonitrile (7a) (87%), as a yellow oil; $R_f 0.67$ (CH₂Cl₂); ¹H NMR $(CDCl_3) \delta 2.34$ (6H, s), 5.04 (1H, s), 7.21 (1H, ddd, J = 7.7, 7.7, 1.7 Hz), 7.33 (1H, ddd, J = 7.7, 7.7, 1.5 Hz), 7.57 (1H, dd, J = 7.7, 1.7 Hz), 7.91 (1H, dd, J = 7.7, 1.5 Hz); ¹³C NMR $(CDCl_3)$ δ 41.1, 62.1, 114.3, 124.3, 127.0, 129.6, 130.2, 132.6, 133.3; FTIR (neat film, cm⁻¹): 2218; EIMS (*m*/*z*, %) 240 (M + 1, 9), 238 (M - 1, 9), 196 (12), 194 (10), 116 (10), 83 (100). Anal. Calcd for C₁₀H₁₁BrN₂: C, 50.23; H, 4.64; N, 11.72. Found: C, 50.31; H, 4.72; N, 11.61.

2-(N,N-Dimethylamino)-2-(2-iodophenyl)acetonitrile (7b) (85%), as a yellow powder; mp 30–32 °C (hexane); R_f0.60 (CH₂Cl₂); ¹H NMR (CDCl₃) δ 2.34 (6H, s), 4.90 (1H, s), 7.07 (1H, ddd, J = 7.6, 7.6, 1.5 Hz), 7.40 (1H, ddd, J = 7.6, 7.6, 1.1 Hz), 7.58 (1H, dd, J = 7.6, 1.5 Hz), and 7.91 (1H, dd, J = 7.6,

⁽³⁹⁾ Ahmad-Junan, S. A.; Whiting, D. A. J. Chem. Soc., Perkin Trans 1 1992. 675-678.

⁽⁴⁰⁾ Lock, G. Monatsch. Chem. 1934, 64, 341-348.

⁽⁴¹⁾ Quelet, R. Bull. Soc. Chim. Fr. 1953, 10, C46-C48.

⁽⁴²⁾ Sindelâr, K.; Metysovay, J.; Protiva, M. Collect. Czech. Chem. Commun. 1972, 37, 1734-1747.

1.1 Hz); ¹³C NMR (CDCl₃) δ 41.0, 66.1, 100.2, 114.4, 127.8, 129.1, 130.2, 132.6, 135.1 (C_{arom} -C), 140.2; FTIR (neat film, cm⁻¹): 2216; EIMS (m/z, %) 286 (M⁺, 24). Anal. Calcd for C₁₀H₁₁IN₂: C, 41.98; H, 3.88; N, 9.79. Found: C, 42.09; H, 3.96; N, 9.86.

2-(N,N-Dimethylamino)-2-(4,5-dimethoxy-2-iodophenyl)acetonitrile (7d) (89%), as a white powder; mp 76–77 °C (MeOH); R_{f} 0.36 (25% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.34 (6H, s), 3.88 (3H, s), 3.91 (3H, s), 4.81 (1H, s), 7.08 (1H, s), 7.30 (1H, s); ¹³C NMR (CDCl₃) δ 41.2, 55.9, 56.0, 66.0, 88.5, 112.0, 115.0, 122.2, 128.0, 148.8, 149.4; FTIR (neat film, cm⁻¹): 2224; EIMS (m/z, %) 346 (M⁺, 24), 302 (100), 176 (15). Anal. Calcd for C₁₂H₁₅IN₂O₂: C, 41.64; H, 4.37; N, 8.09. Found: C, 41.84; H, 4.33; N, 8.22.

Synthesis of Diarylenamines.

(E)-1,2-Bis(2-bromophenyl)-N,N-dimethylethenylamine (15a). Typical Procedure (Method A). A solution of 2-bromobenzyl chloride 8a (5.7 g, 27.6 mmol) in dry degassed DMF (18 mL) was quickly added to a stirred suspension of NaH (95%, 1.39 g, 55.0 mmol) in dry degassed DMF (15 mL) under argon at -19 °C. A solution of α -aminonitrile **7a** (6.0 g, 25.1 mmol) in dry DMF (6 mL) was immediately added to this mixture, as the solution was turning red. After stirring for 15 min at the same temperature, the reaction mixture was allowed to warm to room temperature and stirring was continued for an additional 1.5 h. Water (~30 mL) was added until hydrogen bubbling stopped. Evaporation of the solvent under reduced pressure (1 mmHg, T \sim 90 °C) afforded a brown oil which was purified by flash chromatography using 10% EtOAc/hexane as eluent, providing enamine 15a (8.31 g, 87%) as a white powder, mp 82–83 °C (EtOH); R_f 0.38 (30% CH₂-Cl₂/hexane); ¹H NMR (CDCl₃) & 2.76 (6H, s), 5.60 (1H, s), 6.45-6.49 (1H, m), 6.71-6.75 (2H, m), 7.17-7.21 (3H, m), 7.40-7.44 (1H, m), 7.55 (1H, d, J = 7.5 Hz); ¹³C NMR (CDCl₃) δ 40.0, 102.1, 123.9, 124.7, 125.1, 126.4, 127.5, 129.2, 129.5, 132.1, 132.2, 132.9, 138.0, 138.6, 150.0; FTIR (neat film, cm⁻¹): 1584; EIMS (*m*/*z*, %) 383 (M + 2, 30), 381 (M⁺, 59), 379 (M -2, 29), 302 (71), 300 (100). Anal. Calcd for C₁₆H₁₅Br₂N: C, 50.42; H, 3.97; N, 3.68%). Found: C, 50.81; H, 3.74; N, 3.77.

The same procedure on α -aminonitrile **7b** and chloride **8b** provided (*E*)-*N*,*N*-dimethyl-1,2-bis(2-iodophenyl)ethenylamine **15b** (83%) as a white powder: mp 102–103 °C (Et₂O); *Rf*0.32 (30% CH₂Cl₂/hexane); ¹H NMR (CDCl₃) δ 2.76 (6H, s), 5.49 (1H, s), 6.47 (1H, dd, *J* = 7.9, 1.3 Hz), 6.56 (1H, ddd, *J* = 7.5, 7.5, 1.5 Hz), 6.78 (1H, ddd, *J* = 7.9, 7.9, 0.9 Hz), 6.96 (1H, ddd, *J* = 7.9, 7.9, 1.3 Hz), 7.14 (1H, dd, *J* = 7.5, 1.8 Hz), 7.23 (1H, ddd, *J* = 7.5, 7.5, 1.5 Hz), 6.75, 1.5 Hz), 7.72 (1H, dd, *J* = 7.9, 1.8 Hz), 7.82 (1H, dd, *J* 7.5, 1.8 Hz); ¹³C NMR (CDCl₃) δ 40.0, 100.8, 101.8, 107.1, 125.3, 127.3, 128.2, 128.6, 129.3, 131.5, 138.6, 139.5, 141.4, 141.6, 152.4; FTIR (neat film, cm⁻¹): 1596; EIMS (*m*/*z*, %) 475 (M⁺, 100), 348 (65), 346 (23). Anal. Calcd for C₁₆H₁₅I₂N: C, 40.45; H, 3.18; N, 2.95. Found: C, 40.59; H, 3.09; N, 3.18.

The same procedure on α -aminonitrile **7c** and chloride **8a** provided (*E*)-1-(2-bromo-4,5-dimethoxyphenyl)-2-(2-bromo-phenyl)-*N*,*N*-dimethylethenylamine **15e** (80%) as a red oil: R_f 0.45 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.58 (6H, s), 3.88 (3H, s), 3.90 (3H, s), 5.57 (1H, s), 6.53 (1H, dd, J = 7.5, 2.0 Hz), 6.69 (1H, s), 6.74 (1H, ddd, J = 7.5, 7.5, 2.4 Hz), 6.80 (1H, ddd, J = 7.5, 7.0, 2.0 Hz), 6.97 (1H, s), 7.43 (1H, dd, J = 7.0, 2.4 Hz); ¹³C NMR (CDCl₃) δ 39.4, 55.3, 101.5, 113.6, 114.0, 114.8, 123.2, 124.5, 125.9, 128.4, 129.0, 131.4, 138.1, 147.9, 148.6, 149.3; FTIR (neat film, cm⁻¹): 1594; EIMS (*m*/*z*, %) 443 (M + 2, 46), 441 (M⁺, 92), 439 (M - 2, 47), 362 (92), 360 (100). Anal. Calcd for C₁₈H₁₉Br₂NO₂: C, 49.01; H, 4.34; N, 3.17. Found: C, 49.37; H, 4.31; N, 2.94.

The same procedure on α -aminonitrile **7d** and chloride **8b** provided (*E*)-1-(4,5-dimethoxy-2-iodophenyl)-*N*,*N*-dimethyl-2-(2-iodophenyl)ethenylamine **15f** (80%) as an amber oil: R_f 0.43 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.74 (6H, s), 3.71 (3H, s), 3.83 (3H, s), 5.44 (1H, s), 6.52 (1H, dd, J = 7.3, 1.4 Hz), 6.59 (1H, ddd, J = 7.5, 7.5, 1.4 Hz), 6.66 (1H, s), 6.82 (1H, ddd, J = 7.5, 7.3, 1.2 Hz), 7.17 (1H, s), 7.72 (1H, dd, J = 7.3, 1.2 Hz); ¹³C NMR (CDCl₃) δ 39.9, 55.8, 55.9, 88.3, 101.8, 107.1, 113.7, 121.3, 125.3, 127.3, 128.5, 133.5, 141.6, 148.7, 149.0, 152.1; FTIR (neat film, cm⁻¹): 1589; EIMS (m/z, %) 535 (M⁺, 22), 408 (74). Anal. Calcd for C₁₈H₁₉I₂NO₂: C, 40.40; H, 3.58; N, 2.62. Found: C, 40.72; H, 3.51; N, 2.81.

(E)-1,2-Bis(2-bromo-4,5-dimethoxyphenyl)-N,N-dimethylethenylamine (15c). Typical Procedure (Method B). A solution of α -aminonitrile **7c** (6.8 g, 22.7 mmol) in dry degassed DMF (17 mL) was added dropwise to a stirred suspension of NaH (95%, 1.26 g, 50.0 mmol) in dry degassed DMF (13 mL) under argon at -19 °C. After the mixture was stirred for 1 h at the same temperature, a solution of arylmethyl bromide 17c (12.7 g, 40.9 mmol) in dry degassed DMF (22 mL) was added, and the reaction mixture was stirred for 15 min at -19 °C, warmed to room temperature, and stirred for an additional 1.5 h. Water (~10 mL) was slowly added until bubbling stopped, and the solvent was evaporated in vacuo (1 mmHg, $T \sim 90$ °C). The residue was purified by flash chromatography using 30% EtOAc/hexane as eluent to afford enamine 15c (8.98 g, 79%) as a white powder: mp 138–140 °C (MeOH); R_f 0.57 (40% hexane/EtOAc); ¹H NMR (CDCl₃) δ 2.74 (6H, s), 3.37 (3H, s), 3.73 (3H, s), 3.77 (3H, s), 3.84 (3H, s), 5.49 (1H, s), 6.18 (1H, s), 6.70 (1H, s), 6.90 (1H, s), 6.97 (1H, s); ¹³C NMR (CDCl₃) δ 39.5, 54.6, 55.4, 55.6, 55.7, 101.5, 111.5, 113.0, 113.9, 114.2, 114.3, 114.9, 129.8, 130.6, 145.7, 146.8, 148.2, 148.7; FTIR (neat film, cm⁻¹): 1595; EIMS (m/z, %) 503 (M + 2, 52), 501 (M⁺, 100), 499 (M - 2, 50). Anal. Calcd for C₂₀H₂₃Br₂NO₄: C, 47.93; H, 4.62; N, 2.79. Found: C, 48.09; H, 4.71; N, 2.54.

The same procedure on α-aminonitrile **7d** and bromide **17d** provided (*E*)-1,2-bis(4,5-dimethoxy-2-iodophenyl)-*N*,*N*-dimethylethenylamine **15d** (81%) as a yellow powder: mp 111–112 °C (50% acetone/MeOH); *R*_f0.29 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.74 (6H, s), 3.37 (3H, s), 3.71 (3H, s), 3.76 (3H, s), 3.82 (3H, s), 5.38 (1H, s), 6.20 (1H, s), 6.67 (1H, s), 7.12 (1H, s), 7.18 (1H, s); ¹³C NMR (CDCl₃) δ 39.8, 55.0, 55.8, 55.9, 88.5, 89.1, 106.6, 112.0, 114.0, 120.4, 121.3, 134.1, 134.7, 146.0, 148.1, 148.8, 149.3, 151.5; FTIR (neat film, cm⁻¹): 1598; EIMS (*m*/*z*, %) 595 (M⁺, 4), 469 (100). Anal. Calcd for C₂₀H₂₃I₂NO₄: C, 40.36; H, 3.89; N, 2.35. Found: C, 40.64; H, 3.77; N, 2.49.

The same procedure on α-aminonitrile **7a** and bromide **17c** provided (*E*)-2-(2-bromo-4,5-dimethoxyphenyl)-1-(2-bromo-phenyl)-*N*,*N*-dimethylethenylamine **15g** (79%) as a yellow oil: *R*₇0.44 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.70 (6H, s, 3.25 (3H, s, 3.72 (3H, s, 5.51 (1H, s), 6.05 (1H, s), 6.87 (1H, s), 7.05-7.19 (3H, m), 7.52 (1H, dd, *J* = 7.7, 1.6 Hz); ¹³C NMR (CDCl₃) δ 40.0, 55.0, 55.8, 101.9, 111.9, 113.2, 114.7, 124.5, 127.6, 129.3, 122.0, 132.2, 132.8, 138.2, 145.6, 146.9, 148.9; FTIR (neat film, cm⁻¹): 1571; EIMS (*m*/*z*, %) 443 (M + 2, 51), 441 (M⁺, 100), 439 (M - 2, 52), 428 (18), 426 (35), 424 (21), 362 (68), 360 (78). Anal. Calcd for C₁₈H₁₉Br₂NO₂: C, 49.01; H, 4.34; N, 3.17. Found: C, 49.31; H, 4.36; N, 2.99.

The same procedure on α -aminonitrile **7b** and bromide **17d** provided (*E*)-*N*,*N*-dimethyl-2-(4,5-dimethoxy-2-iodophenyl)-1-(2-iodophenyl)ethenylamine **15h** (78%) as a yellow oil: R_r 0.41 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.74 (6H, s), 3.29 (3H, s), 3.76 (3H, s), 5.42 (1H, s), 6.08 (1H, s), 6.95 (1H, ddd, J = 7.9, 7.9, 1.5 Hz), 7.11–7.17 (2H, m), 7.27 (1H, ddd, J = 7.9, 7.9, 1.4 Hz), 7.83 (1H, dd, J = 7.9, 1.5 Hz); ¹³C NMR (CDCl₃) δ 39.9, 55.0, 55.8, 88.9, 100.6, 106.8, 111.6, 120.5, 128.3, 129.2, 131.5, 134.1, 139.4, 141.9, 146.0, 148.0, 151.6; FTIR (neat film, cm⁻¹): 1598; EIMS (m/z, %) 535 (M⁺, 100), 520 (19), 408 (44). Anal. Calcd for C₁₈H₁₉I₂NO₂: C, 40.40; H, 3.58; N, 2.62. Found: C, 40.66; H, 3.49; N, 2.41.

The same procedure on α-aminonitrile **7a** and bromide **17d** provided (*E*)-1-(2-bromophenyl)-*N*,*N*-dimethyl-2-(4,5-dimethoxy-2-iodophenyl)ethenylamine **15i** (71%) as an amber oil: R_f 0.47 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.75 (6H, s), 3.31 (3H, s), 3.76 (3H, s), 5.44 (1H, s), 6.14 (1H, s, 7.08–7.22 (4H, m), 7.54 (1H, dd, J = 7.9, 1.6 Hz); ¹³C NMR (CDCl₃) δ 40.0, 55.0, 55.8, 89.0, 107.0, 111.5, 120.6, 124.8, 127.5, 129.3, 132.2, 132.7, 134.5, 138.3, 146.1, 148.1, 149.2; FTIR (neat film, cm⁻¹): 1586; EIMS (m/z, %) 489 (M + 1, 33), 487 (M - 1, 34), 362 (17), 360 (23), 291 (100). Anal. Calcd for C₁₈H₁₉BrINO₂: C, 44.29; H, 3.92; N, 2.87. Found: C, 44.64; H, 3.66; N, 2.95.

The same procedure on α -aminonitrile **7b** and bromide **17c** provided (*E*)-2-(2-bromo-4,5-dimethoxyphenyl)-*N*,*N*-dimethyl-1-(2-iodophenyl)ethenylamine **15j** (74%) as a yellow oil: R_f 0.40

(30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.76 (6H, s), 3.27 (3H, s), 3.75 (3H, s), 5.52 (1H, s), 6.04 (1H, s), 6.90 (1H, s), 6.94 (1H, ddd, J = 7.9, 7.5, 1.9 Hz), 7.17 (1H, dd, J = 7.5, 1.9 Hz), 7.25 (1H, ddd, J = 7.5, 7.5, 1.0 Hz), and 7.83 (1H, dd, J = 7.9, 1.0 Hz); ¹³C NMR (CDCl₃) δ 40.4, 55.6, 56.3, 101.0, 102.2, 112.5, 113.8, 115.8, 128.8, 129.7, 131.0, 132.0, 139.9, 142.5, 146.4, 147.6, 152.0; FTIR (neat film, cm⁻¹): 1596. Anal. Calcd for C₁₈H₁₉BrINO₂: C, 44.29; H, 3.92; N, 2.87. Found: C, 44.60; H, 3.84; N, 2.99.

The same procedure on α-aminonitrile **7a** and bromide **17e** provided (*E*)-2-(2-bromo-4,5-methylendioxyphenyl)-1-(2-bromophenyl)-*N*,*N*-dimethylethenylamine **15k** (81%) as a yellow oil: R_f 0.44 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.72 (6H, s), 5.51 (1H, s), 5.76 (2H, s), 5.99 (1H, s), 6.92 (1H, s), 7.15 (1H, ddd, J = 7.7, 7.7, 1.4 Hz), 7.19–7.28 (2H, m), 7.56 (1H, dd, J = 7.5, 1.1 Hz); ¹³C NMR (CDCl₃) δ 40.0, 101.0, 102.4, 118.8, 112.0, 114.2, 124.5, 127.5, 129.5, 132.0, 132.1, 133.0, 137.8, 144.8, 146.4, 149.2; FTIR (neat film, cm⁻¹): 1584; EIMS (*m*/*z*, %) 427 (M + 2, 38), 425 (M⁺, 84), 423 (M – 2, 42), 346 (71), 344 (100). Anal. Calcd for C₁₇H₁₅Br₂NO₂: C, 48.03; H, 3.56; N, 3.29. Found: C, 48.19; H, 3.49; N, 3.58.

2-Bromo-*N*,*N*-dimethylbenzamide (13a) and 2-(2-Bromophenylmethyl)-2,3-bis(2-bromophenyl)propionitrile (14a). Typical Procedure. A solution of α -aminonitrile 7a (0.60 g, 2.51 mmol) in dry DMF (2 mL) was added dropwise to a stirred suspension of NaH (95%, 0.21 g, 3.76 mmol) in dry DMF (3 mL) under argon at 0 °C. After the mixture was stirred for 1 h at the same temperature, a solution of chloride **8a** (0.67 g, 3.26 mmol) in dry DMF (2 mL) was added. The reaction mixture was stirred for 15 min at 0 °C, warmed to room temperature, and stirred for an additional 1.5 h. Water (~5 mL) was added until hydrogen bubbling stopped, and the mixture was evaporated in vacuo (1 mmHg, $T \sim$ 90 °C). Flash chromatography of the residue, eluting with a solvent gradient of 10%, 30%, 50%, 80%, and 95% EtOAc/hexane, afforded the following products:

2-Bromo-*N*,*N***-dimethylbenzamide (13a)** (0.35 g, 62%) as a colorless oil, R_f 0.57 (20% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 2.83 (3H, s), 3.11 (3H, s), 6.98 (1H, d, J = 7.7, 1.5 Hz), 7.17– 7.25 (2H, m), 7.32 (1H, ddd, J = 7.7, 7.3, 1.5 Hz); ¹³C NMR (CDCl₃) δ 34.5, 38.1, 119.0, 127.6, 130.1, 132.6, 138.5, 169.1; FTIR (neat film, cm⁻¹): 1643; EIMS (*m*/*z*, %) 229 (M + 1, 18), 227 (M - 1, 18), 228 (65). Anal. Calcd for C₉H₁₀BrNO: C. 47.39; H. 4.42; N. 6.14. Found: C. 47.42; H. 4.49; N. 6.11.

2-[(2-Bromophenyl)methyl)]-2,3-bis(2-bromophenyl)propionitrile (14a) (0.42 g, 32%) as colorless prismatic crystals: mp 153–154 °C (10% EtOAc/hexane), R_f 0.63 (20% hexane/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.89 (2H, d, J = 14.8 Hz), 4.04 (2H, d, J = 14.9 Hz), 7.03–7.12 (6H, m), 7.20–7.27 (2H, m), 7.43–7.49 (1H, m), 7.55 (2H, m), 7.73 (1H, m); ¹³C NMR (CDCl₃) δ 41.1, 51.6, 120.3, 121.5, 126.3, 127.0, 127.8, 128.8, 130.0, 131.9, 133.1, 134.4, 134.8, 136.3 (C_{arom}-H); FTIR (neat film, cm⁻¹): 2241; EIMS (m/z, %) 537 (M + 3, 5), 535 (M + 1, 15), 533 (M – 1, 15), 531 (M – 3, 5). Anal. Calcd for C₂₂H₁₆-Br₃N: C, 49.47; H, 3.02; N, 2.62. Found: C, 49.53; H, 3.08; N, 2.58.

The same procedure on α -aminonitrile **7b** and chloride **8b** provided the following products:

N,N-Dimethyl-2-iodobenzamide (13b) (65%) as a colorless oil, $R_f 0.42$ (20% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 2.84 (3H, s), 3.13 (3H, s), 7.05 (1H, ddd, J = 7.8, 7.6, 1.8 Hz), 7.20 (1H, dd, J = 7.6, 1.7 Hz), 7.36 (1H, ddd, J = 7.8, 7.6, 1.8 Hz), 7.20 (1H, dd, J = 7.6, 1.7 Hz), 7.36 (1H, ddd, J = 7.8, 7.6, 1.8 Hz), 7.81 (1H, dd, J = 7.8, 1.8 Hz); ¹³C NMR (CDCl₃) δ 34.7, 38.4, 92.4, 126.9, 128.4, 130.0, 139.0, 142.8, 170.7 (CO); FTIR (neat film, cm⁻¹): 1640 (C=O); EIMS (*m*/*z*, %) 275 (M⁺, 45), 231 (100). Anal. Calcd for C₉H₁₀INO: C, 39.30; H, 3.66; N, 5.09. Found: C, 39.45; H, 3.39; N, 5.10.

2-[(2-Iodophenyl)methyl)]-2,3-bis(2-iodophenyl)propionitrile (14b) (31%) as a white powder: mp 193–194 °C (10% EtOAc/hexane), R_f 0.42 (50% hexane/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.73 (2H, d, J = 15.2 Hz), 4.14 (2H, d, J = 15.1 Hz), 6.86–7.34 (8H, m), 7.86 (2H, d, J = 7.8 Hz), 8.12 (2H, d, J = 7.6 Hz); ¹³C NMR (CDCl₃) δ 46.5, 51.6, 94.3, 103.1, 120.1, 127.8, 128.5, 128.9, 130.0, 130.9, 131.9, 136.8, 138.0, 140.1, 144.1; FTIR (neat film, cm⁻¹): 2231; EIMS (m/z, %) 548 (M – I, 3),

421 (12), 217 (100). Anal. Calcd for $C_{22}H_{16}I_3N$: C, 39.14; H, 2.39; N, 2.07. Found: C, 39.23; H, 2.29; N, 2.22.

The same procedure on α -aminonitrile **7c** and chloride **8c** provided the following products:

2-Bromo-*N*,*N***-dimethyl-4,5-dimethoxybenzamide (13c)** (70%) as a colorless oil: $R_f 0.42$ (20% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 2.84 (3H, s), 3.13 (3H, s), 3.84 (3H, s), 3.86 (3H, s), 6.76 (1H, s), 6.98 (1H, s); ¹³C NMR (CDCl₃) δ 34.7, 38.2, 56.1, 56.2, 109.5, 110.3, 115.2, 130.4, 148.7, 149.8, 169.1; FTIR (neat film, cm⁻¹): 1637; EIMS (*m*/*z*, %) 289 (M + 1, 23), 287 (M - 1, 22), 244 (100). Anal. Calcd for C₁₁H₁₄BrNO₃: C, 45.85; H, 4.90; N, 4.86. Found: C, 45.94; H, 5.08; N, 4.67.

2-[(2-Bromo-4,5-dimethoxyphenyl)methyl]-2,3-bis(2-bromo-4,5-dimethoxyphenyl)propionitrile (14c) (28%) as a white powder: mp 193–194 °C (10% EtOAc/hexane); R_{f} 0.49 (5% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.60 (6H, s), 3.73 (2H, d, J = 19.1 Hz), 3.83 (6H, s), 3.90 (6H, s), 3.91 (2H, d, J = 19.1 Hz), 6.58 (2H, s), 6.97 (1H, s), 7.00 (2H, s), 7.15 (1H, s); ¹³C NMR (CDCl₃) δ 40.4, 51.5, 55.7, 55.9, 56.0, 56.3, 113.9, 115.1, 115.3, 116.1, 118.3, 118.4, 121.3, 126.7, 126.8, 147.6, 148.0, 148.5, 149.0; FTIR (neat film, cm⁻¹): 2249; EIMS (m/z, %) 714 (M⁺, 3). Anal. Calcd for C₂₈H₂₈Br₃NO₆: C, 47.09; H, 3.95; N, 1.96. Found: C, 46.88; H, 3.90; N, 1.96.

The same procedure on α -aminonitrile **7d** and chloride **8d** provided the following products:

N,N-Dimethyl-4,5-dimethoxy-2-iodobenzamide (13d) (55%) as a colorless oil: $R_f 0.40$ (35% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 2.85 (3H, s), 3.10 (3H, s), 3.82 (3H, s), 3.85 (3H, s), 6.71 (1H, s), 7.16 (1H, s); ¹³C NMR (CDCl₃) δ 34.7, 38.2, 55.9, 56.2, 80.7, 110.3, 121.1, 135.1, 149.5, 170.6; FTIR (neat film, cm⁻¹): 1637; EIMS (*m*/*z*, %) 335 (M⁺, 52), 291 (100). Anal. Calcd for C₁₁H₁₄INO₃: C, 39.42; H, 4.21; N, 4.18. Found: C, 39.31; H, 4.19; N, 4.55.

2-[(4,5-Dimethoxy-2-iodophenyl)methyl]-2,3-bis(4,5-dimethoxy-2-iodophenyl)propionitrile (14d) (36%) as a white powder: mp 206–207 °C (50% hexane/EtOAc); R_f 0.29 (50% hexane/EtOAc); ¹H NMR (CDCl₃) δ 3.55 (6H, s), 3.63 (3H, s), 3.65 (2H, d, J = 14.8 Hz), 3.80 (6H, s), 3.84 (3H, s), 4.03 (2H, d, J = 14.8 Hz), 6.52 (2H, s), 6.94 (1H, s), 7.23 (2H, s), 7.49 (1H, s); ¹³C NMR (CDCl₃) δ 45.1, 51.9, 55.1, 55.7, 56.2, 81.8, 90.3, 113.5, 115.2, 119.8, 121.7, 130.0, 147.1, 147.4, 148.6; FTIR (neat film, cm⁻¹): 2254; EIMS (m/z, %) 855 (M⁺, 3). Anal. Calcd for C₂₈H₂₈I₃NO₆: C, 39.32; H, 3.30; N, 1.64. Found: C, 39.35; H, 3.41; N, 1.87.

When the same procedure applied on α -aminonitrile **7a** and chloride **8a** was performed with freshly distilled, degassed DMF as solvent, the following products were obtained:

2-[(2-Bromophenyl)methyl)]-2,3-bis(2-bromophenyl)propionitrile (14a) (68%).

(E)-1,2-Bis(2-bromophenyl)-*N,N*-dimethylethenylamine (15a) (25%).

When the same procedure applied on α -aminonitrile **7b** and chloride **8b** was performed with freshly distilled, degassed DMF as solvent, the following products were obtained:

2-[(2-Iodophenyl)methyl)]-2,3-bis(2-iodophenyl)propionitrile (14b) (59%).

(*E*)-*N*,*N*-Dimethyl-1,2-bis(2-iodophenyl)ethenylamine (15b) (31%).

When the same procedure applied on α -aminonitrile **7c** and chloride **8c** was performed with freshly distilled, degassed DMF as solvent, the following products were obtained:

2-[(2-Bromo-4,5-dimethoxyphenyl)methyl]-2,3-bis(2bromo-4,5-dimethoxyphenyl)propionitrile (14c) (63%).

(E)-1,2-Bis(2-bromo-4,5-dimethoxyphenyl)-N,N-dimethylethenylamine (15c) (25%).

2,3-Bis(2-bromo-4,5-dimethoxyphenyl)propionitrile (16) (10%) as a white powder: mp 123–124 °C (10% EtOAc/ hexane); $R_f 0.71$ (5% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.24 (1H, d, J = 6.7 Hz), 3.26 (1H, d, J 7.9 Hz), 3.81 (3H, s), 3.86 (6H, s), 3.87 (3H, s), 4.59 (1H, dd, J = 7.9, 6.7 Hz), 6.73 (1H, s), 6.91 (1H, s), 6.99 (1H,s), 7.00 (1H, s).; ¹³C NMR (CDCl₃) δ 36.7, 39.3, 55.6, 55.7, 55.8, 111.2, 113.2, 113.7, 114.1, 115.1, 116.7, 119.6, 125.6, 126.6, 147.9, 148.6, 149.2; FTIR (neat film, cm⁻¹): 2249; EIMS (m/z, %) 485 (M⁺, 2), 229 (100). Anal. Calcd for $C_{19}H_{19}Br_2NO_4$: C, 47.04; H, 3.95; N, 2.89. Found: C, 46.87; H, 3.89; N, 2.79.

When the same procedure applied on α -aminonitrile **7d** and chloride **8d** was performed with freshly distilled, degassed DMF as solvent, the following products were obtained:

2-[(4,5-Dimethoxy-2-iodophenyl)methyl]-2,3-bis(4,5-dimethoxy-2-iodophenyl)propionitrile (14d) (72%).

(*E*)-1,2-Bis(4,5-dimethoxy-2-iodophenyl)-*N*,*N*-dimethylethenylamine (15d) (22%).

Hydrolysis of Enamines.

1,2-Bis(2-bromophenyl)ethanone (4a). Typical Procedure. A stirred mixture of enamine 15a (7.84 g, 20.6 mmol), HCl (85 mL of a 12.2 M solution in water), and MeOH (15 mL) was heated at 140 °C for 12 h. After being cooled, the mixture was partially concentrated under reduced pressure, extracted with CH_2Cl_2 (3 \times 50 mL), and the combined organic layers were washed with saturated aqueous NaHCO₃ and dried over anhydrous sodium sulfate. Evaporation in vacuo gave a yellow oil which was purified by flash chromatography using 20% EtOAc/hexane as eluent, providing ethanone 4a (6.85 g, 94%) as a white powder: mp 59–60 °C (MeOH); R_f 0.42 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 4.43 (2H, s), 7.20-7.33 (1H, m), 7.37-7.50 (4H, m), 7.52-7.64 (3H, m); ¹³C NMR (CDCl₃) δ 49.6, 118.7, 125.2, 127.5, 128.8, 129.0, 130.3, 131.9, 132.1, 132.7, 133.7, 140.3, 198.8; FTIR (neat film, cm⁻¹): 1690; EIMS (m/z, %) 275 (M - Br,⁷⁹ 4), 273 (M - Br,⁸¹ 4),

185 (100). Anal. Calcd for $C_{14}H_{10}Br_2O$: C, 47.50; H, 2.85. Found: C, 47.59; H, 2.81.

By use of the same procedure, the following products were prepared:

1,2-Bis(2-iodophenyl)ethanone (4b) (95%) as a white powder, mp 79–80 °C (acetone); $R_f 0.57$ (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 4.40 (2H, s), 6.97 (1H, dd, J = 8.0, 7.5 Hz), 7.14 (1H, ddd, J = 7.9, 7.5, 1.2 Hz), 7.32–7.35 (2H, m), 7.38 (1H, ddd, J = 7.5, 7.6, 1.4 Hz), 7.54 (1H, dd, J = 7.6, 1.4 Hz), 7.86 (1H, dd, J = 8.0, 1.2 Hz), 7.93 (1H, dd, J = 7.9, 1.2 Hz); ¹³C NMR (CDCl₃) δ 53.2, 91.2, 101.4, 127.8, 127.9, 128.7, 130.9, 131.6, 137.3, 139.1, 140.4, 143.6, 199.6; FTIR (neat film, cm⁻¹): 1702; EIMS (m/z, %) 321 (M – I, 13), 231 (100). Anal. Calcd for C₁₄H₁₀I₂O: C, 37.53; H, 2.25. Found: C, 37.59; H, 2.26.

1-(2-Bromo-4,5-dimethoxyphenyl)-2-(2-bromophenyl)ethanone (4e) (94%) as a white powder: mp 85–87 °C (MeOH); R_{f} 0.40 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 3.87 (3H, s), 3.92 (3H, s), 4.47 (1H, s), 7.06 (1H, s), 7.12 (1H, s), 7.11–7.18 (1H, m), 7.28–7.31 (2H, m), 7.57 (1H, dd, J = 7.7, 1.2 Hz); ¹³C NMR (CDCl₃) δ 49.2, 56.0, 56.2, 111.2, 112.3, 116.4, 124.9, 127.5, 128.7, 131.8, 132.1, 132.6, 134.8, 147.9, 151.3, 198.0 (CO); FTIR (neat film, cm⁻¹): 1695; EIMS (m/z, %) 246 (10), 245 (85), 243 (100). Anal. Calcd for C₁₆H₁₄Br₂O₃: C, 46.41; H, 3.41. Found: C, 46.78; H, 3.59.

1-(4,5-Dimethoxy-2-iodophenyl)-2-(2-iodophenyl)ethanone (4f) (92%) as a colorless oil: R_f 0.43 (40% EtOAc/ hexane); ¹H NMR (CDCl₃) δ 3.88 (3H, s), 3.91 (3H, s), 4.42 (2H, s), 6.97 (1H, ddd, J = 7.9, 7.9, 2.4 Hz), 7.13 (1H, s), 7.29– 7.37 (3H, m), 7.86 (1H, dd, J = 7.9, 1.4 Hz); ¹³C NMR (CDCl₃) δ 52.8, 56.1, 56.2, 81.9, 101.3, 112.0, 123.3, 128.4, 128.8, 130.9, 138.1, 139.4, 134.6, 148.5, 151.2, 198.1; FTIR (neat film, cm⁻¹):

1691 (C=O); EIMS (m/z, %) 508 (M⁺, 3), 291 (100). Anal. Calcd for $C_{16}H_{14}I_2O_3$: C, 37.82; H, 2.78. Found: C, 37.98; H, 2.88.

2-(2-Bromo-4,5-dimethoxy)-1-(2-bromophenyl)ethanone (4g) (91%) as a white powder: mp 115–118 °C (MeOH); R_{f} 0.54 (50% hexane/EtOAc); ¹H NMR (CDCl₃) δ 3.86 (6H, s), 4.33 (2H, s), 6.80 (1H, s), 7.02 (1H, s), 7.31 (1H, ddd, J = 7.7, 7.6, 1.9 Hz), 7.37 (1H, ddd, J = 7.6, 7.6, 1.3 Hz), 7.46 (1H, dd, J = 7.6, 1.9 Hz), 7.61 (1H, dd, J = 7.7, 1.3 Hz); ¹³C NMR (CDCl₃) δ 49.1, 56.0, 114.0, 115.0, 115.3, 118.6, 125.7, 127.3, 128.5, 131.6, 133.5, 141.0, 148.3, 148.7, 200.2; FTIR (neat film, cm⁻¹): 1701; EIMS (m/z, %) 335 (M – Br,⁷⁹ 28), 333 (M – Br,⁸¹ 29). Anal. Calcd for C₁₆H₁₄Br₂O₃: C, 46.41; H, 3.41. Found: C, 46.26; H, 3.47.

2-(4,5-Dimethoxy-2-iodophenyl)-1-(2-iodophenyl)ethanone (4h) (89%) as a yellow powder: mp 83–85 °C (MeOH); R_f 0.37 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 3.85 (6H, s), 4.33 (2H, s), 6.81 (1H, s), 7.13 (1H, ddd, J = 7.7, 7.7, 2.0 Hz), 7.22 (1H, s), 7.41 (1H, ddd, J = 7.9, 7.7, 2.0 Hz), 7.51 (1H, dd, J = 7.7, 2.0 Hz), 7.92 (1H, d, J = 7.9, 1.9 Hz); ¹³C NMR (CDCl₃) δ 52.9, 55.9, 56.0, 89.3, 91.4, 113.1, 121.3, 127.9, 128.0, 129.5, 131.7, 140.5, 143.6, 148.5, 149.2, 200.7; FTIR (neat film, cm⁻¹): 1701; EIMS (*m*/*z*, %) 381 (M – I, 49). Anal. Calcd for C₁₆H₁₄-I₂O₃: C, 37.82; H, 2.78. Found: C, 37.69; H, 2.91.

1-(2-Bromophenyl)-2-(4,5-dimethoxy-2-iodophenyl)ethanone (4i) (85%) as a yellow powder: mp 88–90 °C (MeOH); R_{f} 0.39 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 3.85 (6H, s), 4.34 (2H, s), 6.81 (1H, s), 7.22 (1H, s), 7.30 (1H, ddd, J = 7.6, 7.6, 1.9 Hz), 7.36 (1H, ddd, J = 7.5, 7.6, 1.5 Hz), 7.48 (1H, dd, J = 7.5, 1.9 Hz), 7.61 (1H, dd, J 7.5, 1.5 Hz); ¹³C NMR (CDCl₃) δ 53.5, 55.8, 56.0, 89.2, 113.3, 118.0, 121.4, 127.2, 128.6, 129.6, 131.5, 133.5, 141.0, 148.5, 149.2, 200.0; FTIR (neat film, cm⁻¹): 1702; EIMS (m/z, %) 462 (M + 1, 14), 460 (M - 1, 14) 335 (42), 333 (41). Anal. Calcd for C₁₆H₁₄BrIO₃: C, 41.68; H, 3.06. Found: C, 41.84; H, 2.97.

2-(2-Bromo-4,5-dimethoxy)-1-(2-iodophenyl)ethanone (**4j**) (89%) as a white powder: mp 112–114 °C (MeOH), R_f 0.37 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 3.85 (6H, s), 4.30 (2H, s), 6.81 (1H, s), 7.02 (1H, s), 7.12 (1H, ddd, J = 7.9, 7.5, 1.9 Hz), 7.39 (1H, ddd, J = 7.5, 7.5, 1.0 Hz), 7.48 (1H, dd, J = 7.5, 1.9 Hz), 7.90 (1H, dd, J = 7.9, 1.0 Hz); ¹³C NMR (CDCl₃) δ 48.3, 56.0, 91.3, 113.9, 115.0, 115.4, 125.5, 127.9, 128.0, 131.7, 140.6, 143.8, 148.4, 148.8, 200.7; FTIR (neat film, cm⁻¹): 1701; EIMS (m/z, %) 381 (M + 1 – Br,⁸¹ 41). Anal. Calcd for C₁₆H₁₄-BrIO₃: C, 41.68; H, 3.06. Found: C, 41.79; H, 3.09.

1,2-Bis(2-bromo-4,5-dimethoxyphenyl)ethanone (4c). Typical Procedure. A stirred mixture of enamine 15c (8.98 g, 17.9 mmol), HCl (73 mL of a 6.0 M solution in water), and MeOH (13 mL) was heated at 115 °C for 9 h. After being cooled, the mixture was partially concentrated under reduced pressure, extracted with CH_2Cl_2 (3 \times 50 mL), and the combined organic layers were washed with saturated aqueous NaHCO₃ and dried over anhydrous sodium sulfate. Evaporation in vacuo gave a yellow oil which was purified by flash chromatography using 40% EtOAc/hexane as eluent, providing ethanone 4c (7.64 g, 90%) as a white powder: mp 130-131 °C (MeOH) (lit.^{11b} 130–132 °C); R_f 0.30 (40% EtOAc/hexane); ¹H NMR (CDCl₃) & 3.85 (6H, s), 3.87 (3H, s), 3.91 (3H, s), 4.36 (2H, s), 6.81 (1H, s), 7.02 (1H, s), 7.05 (1H, s), 7.10 (1H, s); ¹³C NMR $(CDCl_3) \delta 48.7, 55.9, 56.0, 56.1, 56.2, 111.1, 112.3, 113.8, 114.8,$ 115.3, 116.3, 126.4, 132.1, 147.9, 148.3, 148.6, 151.3, 198.6; FTIR (neat film, cm⁻¹): 1690; EIMS (*m*/*z*, %) 474 (M⁺, 3). Anal. Calcd for C₁₈H₁₈Br₂O₅: C, 45.60; H, 3.83. Found: C, 45.54; H, 3.87.

By use of the same procedure, the following compounds were prepared:

1,2-Bis(4,5-dimethoxy-2-iodophenyl)ethanone (4d) (94%) as a white powder: mp 137–139 °C (acetone/MeOH); R_f 0.16 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 3.84 (6H, s), 3.90 (6H, s), 4.33 (2H, s), 6.79 (1H, s), 7.10 (1H, s), 7.21 (1H, s), 7.32 (1H, s); ¹³C NMR (CDCl₃) δ 52.2, 55.9, 56.0, 56.1, 85.8, 89.0, 111.9, 113.3, 121.7, 123.4, 130.3, 134.4, 148.6, 148.7, 149.2, 151.1, 198.4; FTIR (neat film, cm⁻¹): 1683; EIMS (*m*/*z*, %) 441 (M – I, 10), 291 (100). Anal. Calcd for C₁₈H₁₈I₂O₅: C. 38.05; H. 3.19. Found: C, 38.09; H, 3.12.

2-(2-Bromo-4,5-methylendioxyphenyl)-1-(2-bromophenyl)ethanone (4k) (95%) as a colorless oil: R_{f} 0.40 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 4.31 (2H, s), 5.98 (2H, s), 6.81 (1H, s), 7.02 (1H, s), 7.30 (1H, ddd, J = 7.7, 7.5, 1.9 Hz), 7.37 (1H, ddd, J = 7.6, 7.5, 1.4 Hz), 7.48 (1H, dd, J = 7.5, 1.9 Hz), 7.62 (1H, dd, J = 7.7, 1.4 Hz); ¹³C NMR (CDCl₃) δ 49.3, 101.7, 111.1, 112.5, 115.4, 118.5, 126.6, 127.3, 128.5, 131.6, 133.5, 141.0, 147.3, 147.6, 200.5; FTIR (neat film, cm⁻¹): 1701; EIMS (m/z, %) 319 (M – Br,⁷⁹ 34), 317 (M – Br,⁸¹ 34). Anal. Calcd for C₁₅H₁₀Br₂O₃: C. 45.26; H. 2.53. Found: C, 45.28; H, 2.59. **Synthesis of Enaminoketones**.

1,2-Bis(2-bromophenyl)-3-(*N***,***N***-dimethylamino)propenone (18a). Typical Procedure. DMFDMA (4.54 mL, 325 mmol) was added dropwise to a stirred suspension of ketone 4a** (8.8 g, 25 mmol) in dry toluene (30 mL) under argon at room temperature. The resulting mixture was heated at 135 °C for 16 h, and after being cooled, it was concentrated in vacuo to give a brown oil which was purified by flash chromatography using 50% EtOAc/hexane as eluent. Enaminoketone **18a** (7.873 g, 77%) was obtained as orange glassy solid: mp 41–42 °C (Et₂O); R_f 0.32 (50% hexane/EtOAc); ¹H NMR (CDCl₃) δ 2.41–2.84 (6H, bs), 7.42–7.03 (6H, m, H_{arom}), 7.49 (1H, dd, J = 8.4, 1.4 Hz), 7.52 (1H, dd, J = 8.1, 8.1 Hz); ¹³C NMR (CDCl₃) δ 38.5, 47.1, 111.2, 119.4, 126.4, 126.9, 128.2, 129.0, 131.4, 132.2, 133.6, 136.9, 142.6, 154.5, 191.2; FTIR (neat film, cm⁻¹): 1635, 1576; EIMS (m/z, %) 411 (M + 2, 6), 409 (M⁺, 11), 407 (M – 2, 25), 330 (84), 328 (100). Anal. Calcd for C₁₇H₁₅Br₂NO: C, 49.91; H, 3.70; N, 3.42. Found: C, 50.08; H, 3.39; N, 3.21.

By use of the same procedure, the following compounds were prepared:

3-(*N*,*N*-Dimethylamino)-1,2-bis(2-iodophenyl)propenone (18b) (78%), as a white glassy solid: mp 59–60 °C (Et₂O); R_f 0.40 (50% hexane/EtOAc); ¹H NMR (CDCl₃) δ 2.37–2.65 (6H, bs), 6.95–6.84 (3H, m), 7.21–7.38 (4H, m, H_{arom}), 7.76 (2H, m); ¹³C NMR (CDCl₃) δ 43.0 (bs), 93.4, 105.2, 113.9, 127.0, 128.0, 128.9, 132.4, 137.5, 138.4, 141.0, 146.2, 154.0, 192.2; FTIR (neat film, cm⁻¹): 1637, 1569; EIMS (*m*/*z*, %) 503 (M⁺, 11), 377 (18), 376 (100). Anal. Calcd for C₁₇H₁₅I₂NO: C, 40.58; H, 3.01; N, 2.78. Found: C, 40.39; H, 3.29; N, 2.64.

1,2-Bis(2-bromo-4,5-dimethoxyphenyl)-3-(*N*,*N***-dimethylamino)propenone (18c)** (75%), as a yellow powder: mp 173–174 °C (Et₂O); R_f 0.33 (30% hexane/EtOAc); ¹H NMR (CDCl₃) δ 2.39–3.12 (6H, bs), 3.77 (3H, s), 3.90 (9H, s), 6.76 (1H, s), 6.82 (2H, s), 6.88 (1H, s), 6.94 (1H, s); ¹³C NMR (CDCl₃) δ 39.4, 46.8, 55.4, 109.4, 110.6, 113.9, 114.7, 116.0, 117.0, 129.6, 135.2, 147.3, 148.1, 148.6, 152.6, 191.2; FTIR (neat film, cm⁻¹): 1643, 1572; EIMS (*m*/*z*, %) 531 (M + 2, 5), 529 (M⁺, 10), 526 (M - 2, 6), 450 (100), 448 (100). Anal. Calcd for C₂₁H₂₃Br₂-NO₅: C, 47.66; H, 4.38; N, 2.65. Found: C, 48.64; H, 4.49; N, 2.48.

3-(*N*,*N*-Dimethylamino)-1,2-bis(4,5-dimethoxy-2-iodophenyl)propenone (18d) (70%), as a white powder: mp 202–203 °C (Et₂O); R_f 0.25 (40% hexane/EtOAc); ¹H NMR (CDCl₃) δ 2.57–3.02 (6H, bs), 3.75 (6H, s), 3.78 (6H, s), 6.76 (1H, s), 6.83 (1H, s), 7.08 (2H, s), 7.13 (1H, s); ¹³C NMR (CDCl₃) δ 38.7, 46.9, 55.9, 82.0, 94.2, 110.4, 111.0, 115.6, 119.8, 120.8, 139.7, 148.1, 148.3, 148.6, 148.8, 152.6, 193.7; FTIR (neat film, cm⁻¹): 1638, 1565; EIMS (*m/z*, %) 623 (M⁺, 3), 496 (100),. Anal. Calcd for C₂₁H₂₃I₂NO₅: C, 40.47; H, 3.72; N, 2.25; Found: C, 40.79; H, 3.86; N, 2.19.

1-(2-Bromo-4,5-dimethoxyphenyl)-2-(2-bromophenyl)-3-(*N*,*N*-**dimethylamino)propenone (18e)** (79%), as a white powder: mp 73–75 °C (Et₂O); R_f 0.35 (30% hexane/EtOAc); ¹H NMR (CDCl₃) δ 2.47–3.13 (6H, bs), 3.78 (3H, s), 3.84 (3H, s), 6.78 (1H, s), 6.93 (1H, s), 7.05–7.34 (4H, m), 7.54 (1H, m); ¹³C NMR (CDCl₃) δ 39.0, 46.3, 55.8, 56.0, 110.1, 110.9, 115.0, 126.8, 127.3, 128.6, 131.7, 134.1, 135.1, 137.1, 145.1, 137.9, 147.5, 148.9, 153.5, 191.6; FTIR (neat film, cm⁻¹): 1639, 1575; EIMS (*m*/*z*, %) 471 (M + 2, 5), 469 (M⁺, 10), 467 (M + 2, 5), 390 (84), 388 (100). Anal. Calcd for C₁₉H₁₉Br₂NO₃: C, 48.64; H, 4.08; N, 2.99. Found: C, 48.98; H, 3.92; N, 2.94.

3-(*N*,*N***-Dimethylamino)-1-(4,5-dimethoxy-2-iodophenyl)-2-(2-iodophenyl)propenone (18f)** (71%), as a yellow oil: R_f 0.42 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.47–3.12 (6H, bs), 3.79 (3H, s), 3.83 (3H, s), 6.82–6.88 (2H, m), 7.15 (1H, m), 7.35 (1H, m), 7.79–7.82 (3H, m); ¹³C NMR (CDCl₃) δ 37.2, 47.8, 55.8, 82.1, 105.7, 110.6, 112.6, 120.8, 127.4, 128.2, 132.8, 137.7, 138.9, 141.5, 148.1, 148.5, 154.4, 192.5 (CO); FTIR (neat film, cm⁻¹): 1637, 1572; EIMS (m/z, %) 563 (M⁺, 100), 437 (22), 436 (100). Anal. Calcd for C₁₉H₁₉I₂NO₃: C, 40.52; H, 3.40; N, 2.49. Found: C, 40.77; H, 3.31; N. 2.59.

2-(2-Bromo-4,5-dimethoxyphenyl)-1-(2-bromophenyl)-3-(*N*,*N***-dimethylamino)propenone (18g)** (81%) as a white glassy solid: mp 65–67 °C (50% hexane/EtOAc); R_f 0.35 (30% hexane/EtOAc); ¹H NMR (CDCl₃) δ 2.52–2.94 (6H, bs), 3.74 (6H, s), 6.86 (1H, s), 6.97–7.24 (4H, m), 7.39–7.45 (2H, m); ¹³C NMR (CDCl₃) δ 38.0, 47.0, 55.8, 114.2, 115.9, 117.2, 118.4, 126.5, 129.1, 132.1, 143.2, 147.5, 148.3, 153.0, 191.9; FTIR (neat film, cm⁻¹): 1637, 1576; EIMS (*m*/*z*, %) 469 (M⁺, 5), 390 (98), 388 (100). Anal. Calcd for C₁₉H₁₉Br₂NO₃: C, 48.64; H, 4.08; N, 2.99. Found: C, 48.79; H, 4.12; N, 2.88. **3**-(*N*,*N*-Dimethylamino)-2-(4,5-dimethoxy-2-iodophenyl)- **1**-(2-iodophenyl)propenone (18h) (86%) as a yellow glassy solid: mp 168–170 °C (Et₂O); R_f 0.40 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.54–3.13 (6H, bs), 3.84 (6H, s), 6.73–7.28 (5H, m), 6.73–7.28 (5H, m), 7.73–7.76 (2H, m); ¹³C NMR (CDCl₃) δ 37.2, 47.3, 55.4, 93.5, 114.6, 119.6, 127.0, 129.0, 134.4, 138.3, 147.8, 148.1, 154.7, 193.0; FTIR (neat film, cm⁻¹): 1639, 1575; EIMS (*m/z*, %) 563 (M⁺, 4), 436 (100). Anal. Calcd for C₁₉H₁₉I₂NO₃: C, 40.52; H, 3.40; N, 2.49. Found: C, 40.36; H, 3.62; N, 2.52.

1-(2-Bromophenyl)-3-(*N*,*N*-dimethylamino)-2-(**4**,**5**-dimethoxy-2-iodophenyl)propenone (18i) (82%): as a white powder: mp 168–170 °C (EtOAc); R_f 0.50 (20% hexane/EtOAc); ¹H NMR (CDCl₃) δ 2.56–2.85 (6H, bs), 3.83 (6H, s), 6.89 (1H, s), 7.19–7,0.1 (5H, m), 7.44 (1H, m); ¹³C NMR (CDCl₃) δ 36.9, 47.6, 55.7, 55.8, 94.2, 115.1, 119.6, 120.1, 126.6, 129.1, 132.3, 133.7, 143.1, 148.2, 148.4, 154.8, 191.8; FTIR (neat film, cm⁻¹): 1637, 1576; EIMS (*m*/*z*, %) 517 (M + 1, 1), 515 (M – 1, 1), 390 (100), 388 (100). Anal. Calcd for C₁₉H₁₉-BrINO₃: C, 44.21; H, 3.71; N, 2.71. Found: C, 44.47; H, 3.66; N, 2.89.

2-(2-Bromo-4,5-dimethoxyphenyl)-3-(*N*,*N***-dimethylami-no)-1-(2-iodophenyl)propenone (18j)** (77%) as a white powder: mp 167–169 °C (Et₂O); *R*_{*t*}0.42 (20% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 2.54–2.97 (6H, bs), 3.82 (6H, s), 6.87–7.31 (6H, m), 7.73 (1H, s); ¹³C NMR (CDCl₃) δ 37.0, 47.0, 55.4, 93.1, 110.1, 113.7, 114.6, 115.5, 126.9, 128.7, 138.0, 146.4, 146.7, 147.8, 155.4, 192.9; FTIR (neat film, cm⁻¹): 1639, 1574; EIMS (*m*/*z*, %) 516 (M⁺, 3), 436 (100). Anal. Calcd for C₁₉H₁₉-BrINO₃: C, 44.21; H, 3.71; N, 2.71. Found: C, 44.37; H, 3.89; N, 2.75.

2-(2-Bromo-4,5-methylendioxyphenyl)-1-(2-bromophenyl)-3-(*NN***-dimethylamino)propenone (18k)** (84%) as a yellow glassy solid: mp 75–76 °C (MeOH); *R^f* 0.37 (40% EtOAc/hexane); ¹H NMR (CDCl₃) δ 2.57–2.87 (6H, bs), 5.96 (2H, s), 6.86 (1H, s), 7.02–7.30 (4H, m), 7.52 (1H, m); ¹³C NMR (CDCl₃) δ 39.6, 46.8, 107.2, 111.8, 113.1, 117.7, 119.8, 125.6, 126.8, 128.9, 129.4, 142.9, 146.8, 147.6, 160.0, 193.5 (CO); FTIR (neat film, cm⁻¹): 1636, 1576; EIMS (*m*/*z*, %) 455 (2), 453 (2), 451 (M⁺, 3), 374 (100), 372 (97). Anal. Calcd for C₁₈H₁₅BrNO₃: C, 47.71; H, 3.34; N, 3.09. Found: C, 47.88; H, 3.36; N, 3.21.

Heterocyclization to Isoxazoles.

4,5-Bis(2-bromophenyl)isoxazole (21a). Typical Procedure. Ground Na₂CO₃ (0.462 g, 4.31 mmol) and NH₂OH· HCl (5.65 g, 66.0 mmol) were added to a solution of enaminoketone 18a (2.71 g, 6.60 mmol) in dry methanol (100 mL)⁴³ in a heavy-wall screw capped tube at room temperature. The resulting mixture was acidified with glacial acetic acid (2.6 mL) to pH \sim 4, and after closing the tube, it was heated at 115 °C for 2 h in a oven. After being cooled, the suspension was filtered, the filtrate washed with dichloromethane (100 mL), and the filtrate was evaporated in vacuo. The residue was redissolved with water (40 mL) and extracted with CH2- Cl_2 (5 \times 15 mL), and the combined organic layers were washed with brine and water. The organic layers were dried over anhydrous sodium sulfate and evaporated under reduced pressure, and the resulting yellow residue was triturated with methanol to afford isoxazole 21a (2.301 g, 92%) as yellow flakes: mp 58–60 °C (MeOH); R_f 0.82 (6% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) & 7.03-7.06 (1H, m), 7.15-7.18 (2H, m), 7.25-7.36 (3H, m), 7.56-7.62 (2H, m), 8.56 (1H, s); 13C NMR (CDCl₃) δ 117.4, 122.8, 123.3, 127.4, 127.6, 128.5, 129.7, 131.5, 131.6, 131.8, 133.2, 133.5, 151.3, 164.8; FTIR (neat film, cm⁻¹): 1583; EIMS (m/z, %) 381 (M + 2, 33), 379 (M⁺, 64), 377 (M - 2, 34), 300 (22), 298 (21). Anal. Calcd for C₁₅H₉Br₂NO: C, 47.53; H, 2.39; N, 3.70. Found: C, 47.81; H, 2.30; N, 3.61.

By use of the same procedure, the following compounds were prepared:

4,5-Bis(2-iodophenyl)isoxazole (21b) (90%) as a yellow powder: mp 129–130 °C (MeOH); R_f 0.80(6% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 7.00–7.32 (6H, m), 7.89 (1H, dd, J = 7.9,

^{(43) 2-}Propanol was used as solvent in the synthesis of isoxazoles ${\bf 18d}$ and ${\bf 18f}.$

1.5 Hz), 7.92 (1H, dd, J = 7.1, 1.2 Hz), 8.56 (s, 1H); ¹³C NMR (CDCl₃) δ 97.2, 99.5, 120.0, 128.2, 128.9, 129.7, 131.1, 131.2, 132.6, 134.1, 139.6, 151.3, 166.6; FTIR (neat film, cm⁻¹): 1577; EIMS (*m*/*z*, %) 473 (M⁺, 90), 346 (55), 219 (100). Anal. Calcd for C₁₅H₉I₂NO: C, 38.09; H, 1.92; N, 2.96. Found: C, 38.16; H. 1.79; N, 3.09.

4,5-Bis(2-bromo-4,5-dimethoxyphenyl)isoxazole (21c) (89%) as a white powder: mp 167–168 °C (MeOH); R_f 0.71 (6% EtOAc/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.59 (3H, s), 3.75 (3H, s), 3.84 (3H, s), 3.86 (3H, s), 6.54 (1H, s), 6.84 (1H, s), 7.02 (1H, s), 7.04 (1H, s), 8.51 (1H, s); ¹³C NMR (CDCl₃) δ 55.6, 55.8, 55.9, 56.0, 113.5, 113.6, 115.4, 115.6, 117.1, 120.4, 122.3, 148.0, 148.1, 149.1, 150.6, 151.2, 164.6; FTIR (neat film, cm⁻¹):

1597; EIMS (m/z, %) 501 (M + 2, 9), 499 (M⁺, 18), 497 (M - 2, 9), 419 (18), 417 (16), 339 (100). Anal. Calcd for C₁₉H₁₇Br₂-NO₅: C, 45.72; H, 3.43; N, 2.81. Found: C, 45.86; H, 3.21; N, 2.76.

4,5-Bis(4,5-dimethoxy-2-iodophenyl)isoxazole (21d) (98%) as a white powder: mp 179–181 °C (MeOH); R_f 0.52 (50% hexane/EtOAc); ¹H NMR (CDCl₃) δ 3.63 (3H, s), 3.75 (3H, s), 3.86 (3H, s), 3.87 (3H, s), 6.66 (1H, s), 6.80 (1H, s), 7.27 (2H, s), 8.51 (1H, s); ¹³C NMR (CDCl₃) δ 55.7, 55.8, 56.0, 56.1, 86.0, 87.7, 113.7, 119.7, 121.4, 121.6, 124.5, 124.9, 148.7, 148.9, 149.0, 150.4, 151.3, 166.7; FTIR (neat film, cm⁻¹): 1590; EIMS (*m*/*z*, %) 593 (M⁺, 18), 465 (11), 339 (100). Anal. Calcd for C₁₉H₁₇I₂NO₅: C, 38.47; H, 2.89; N, 2.36. Found: C, 38.31; H, 2.99; N, 2.19.

4-(2-Bromophenyl)-5-(2-bromo-4,5-dimethoxyphenyl)isoxazole (21e) (91%) as a white powder: mp 58–60 °C (MeOH); $R_{\rm f}$ 0.35 (20% hexane/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.76 (3H, s), 3.89 (3H, s), 6.86 (1H, s), 6.88 (1H, s), 7.06 (1H, dd, J = 6.5, 2.3 Hz), 7.18–7.23 (2H, m), 7.65 (1H, dd, J = 6.7, 2.4 Hz), 8.55 (1H, s); ¹³C NMR (CDCl₃) δ 55.8, 56.7, 113.2, 113.3, 115.6, 117.0, 119.9, 123.3, 127.3, 129.4, 130.5, 131.2, 132.9, 147.8, 150.5, 151.1, 164.7; FTIR (neat film, cm⁻¹): 1598; EIMS (m/z, %) 441 (M + 2, 19), 439 (M⁺, 39), 437 (M – 2, 20), 279 (100). Anal. Calcd for C₁₇H₁₃Br₂NO₃: C, 46.50; H, 2.98; N, 3.29. Found: C, 46.57; H, 3.31; N, 3.29.

5-(4,5-Dimethoxy-2-iodophenyl)-4-(2-iodophenyl)isox-azole (21f) (89%) as a colorless oil: R_f 0.48 (20% hexane/CH₂-Cl₂); ¹H NMR (CDCl₃) δ 3.72 (3H, s), 3.88 (3H, s), 6.78 (1H, s), 6.99–7.09 (2H, m), 7.24–7.30 (2H, m), 7.92 (1H, dd, J = 7.1, 1.7 Hz), 8.54 (1H, s); ¹³C NMR (CDCl₃) δ 55.8, 56.1, 85.7, 99.8, 113.8, 119.7, 122.0, 124.7, 128.3, 129.7, 131.2, 134.6, 139.7, 148.8, 150.5, 151.4, 166.7 (C-5); FTIR (neat film, cm⁻¹): 1592; EIMS (m/z, %) 533 (M⁺, 32), 291 (70), 279 (100). Anal. Calcd for C₁₇H₁₃I₂NO₃: C, 38.30; H, 2.46; N, 2.63. Found: C, 38.49; H, 2.20; N, 2.80.

4-(2-Bromo-4,5-dimethoxyphenyl)-5-(2-bromophenyl)isoxazole (21g) (92%) as a white powder: mp 65–67 °C (MeOH); R_7 0.51 (20% hexane/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.56 (3H, s), 3.86 (3H, s), 6.51 (1H, s), 7.06 (1H, s), 7.26–7.38 (3H, m), 7.64 (1H, dd, J = 6.7, 1.6 Hz), 8.59 (1H, s); ¹³C NMR (CDCl₃) δ 55.8, 56.1, 113.7, 115.7, 117.8, 122.2, 123.3, 127.4, 129.2, 131.6, 131.9, 133.4, 148.2, 149.4, 151.4, 164.9; FTIR (neat film, cm⁻¹): 1601; EIMS (m/z, %) 441 (M + 2, 40), 439 (M⁺, 78), 437 (M – 2, 43), 360 (31), 358 (29). Anal. Calcd for C₁₇H₁₃Br₂NO₃: C, 46.50; H, 2.98; N, 3.19. Found: C, 46.57; H, 2.91; N, 3.29.

4-(4,5-Dimethoxy-2-iodophenyl)-5-(2-iodophenyl)isox-azole (21h) (88%) as a white powder: mp 120–122 °C (MeOH); R_f 0.37 (30% EtOAc/hexane); ¹H NMR (CDCl₃) δ 3.58 (3H, s), 3.85 (3H, s), 6.54 (1H, s), 7.13 (1H, dd, J = 7.9, 7.6 Hz), 7.26–7.30 (2H, m), 7.38 (1H, dd, J = 7.6, 7.6 Hz), 7.91 (1H, d, J = 7.9 Hz), 8.58 (1H, s),; ¹³C NMR (CDCl₃) δ 55.6, 55.9, 87.3, 97.5, 113.5, 119.9, 121.5, 126.1, 127.9, 131.4, 132.9, 139.6, 148.8, 149.0, 151.2, 166.7; FTIR (neat film, cm⁻¹): 1594; EIMS (m/z, %) 533 (M⁺, 100), 406 (19). Anal. Calcd for C₁₇H₁₃I₂-NO₃: C, 38.30; H, 2.46; N, 2.63. Found: C, 38.19; H, 2.59; N, 2.77.

5-(2-Bromophenyl)-4-(4,5-dimethoxy-2-iodophenyl)isoxazole (21i) (81%) as a white powder: mp 60–62 °C (MeOH); R_{f} 0.41 (20% hexane/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.59 (3H, s), 3.86 (3H, s), 6.54 (1H, s), 7.27–7.42 (4H, m), 7.63 (1H, dd, J = 7.9, 2.0 Hz), 8.56 (1H, s); ¹³C NMR (CDCl₃) δ 55.6,

56.0, 87.3, 113.4, 120.5, 121.6, 123.2, 126.4, 127.3, 128.9, 131.6, 131.8, 133.4, 149.0, 149.1, 151.4, 164.7; FTIR (neat film, cm⁻¹): 1586; EIMS (m/z, %) 487 (M + 1, 26), 485 (M - 1, 27), 359 (21). Anal. Calcd for C₁₇H₁₃BrINO₃: C, 42.00; H, 2.70; N, 2.88. Found: C, 42.09; H, 2.64; N, 2.86.

4-(2-Bromo-4,5-dimethoxyphenyl)-5-(2-iodophenyl) isoxazole (21j) (78%) as a white powder: mp 68–70 °C (MeOH); R_{f} 0.41 (20% hexane/CH₂Cl₂); ¹H NMR (CDCl₃) δ 3.54 (3H, s), 3.87 (3H, s), 6.50 (1H, s), 7.06 (1H, s), 7.14 (1H, ddd, J = 7.9, 7.9, 2.0 Hz), 7.30 (1H, dd, J = 7.6, 1.6 Hz), 7.39 (1H, 1, 32.6, 139.3, 147.6, 148.8, 150.8, 166.5 (C-5); FTIR (neat film, cm⁻¹): 1600 (C=N); EIMS (m/z, %) 487 (M + 1, 22), 485 (M - 1, 23), 406 (17). Anal. Calcd for C₁₇H₁₃BrINO₃: C, 42.00; H, 2.70; N, 2.88. Found: C, 42.31; H, 2.35; N, 2.76.

4-(5-Bromo-1,3-benzodioxol-6-yl)-5-(2-bromophenyl)isoxazole (21k) (93%) as a colorless oil: R_f 0.43 (20% hexane/ CH₂Cl₂); ¹H NMR (CDCl₃) δ 5.96 (2H, s), 6.50 (1H, s), 7.07 (1H, s), 7.29–7.38 (3H, m), 7.64 (1H, dd, J = 6.4, 1.6 Hz), 8.50 (1H, s); ¹³C NMR (CDCl₃) δ 101.9, 110.6, 113.0, 114.4, 117.5, 122.8, 123.0, 127.3, 128.5, 131.5, 131.7, 133.4, 147.2, 148.3, 151.5, 164.6; FTIR (neat film, cm⁻¹): 1586; EIMS (m/z, %) 425 (M + 2, 13), 423 (M⁺, 25), 421 (M – 2, 14), 342 (19). Anal. Calcd for C₁₆H₉Br₂NO₃: C, 45.42; H, 2.14; N, 3.31. Found: C, 45.31; H, 2.19; N, 3.26.

Heterocyclization Procedures Leading to Ketones 4 and Hydroxyisoxazolines 21.

4,5-Bis(2-bromophenyl)-5-hydroxy-2-isoxazoline (22a) and 1,2-Bis(2-bromophenyl)ethanone (4a). Typical Procedure. NH₂OH·HCl (210 mg, 3.15 mmol) and Na₂CO₃ (170 mg, 1.6 mmol) were added to a stirred solution of enaminoketone 18a (1.17 g, 2.86 mmol) in methanol (30 mL) and water (15 mL) at room temperature. The reaction mixture was acidified with glacial acetic acid up to pH 4-5 and refluxed for 11 h. After being cooled, the reaction mixture was basified to pH 8 with ammonium hydroxide solution and extracted with dichloromethane (4 \times 30 mL). The organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuo (T < 30 °C). The residue (A) crystallized from 50% EtOAc/ hexane, providing pure isoxazoline 22a (658 mg, 58%) as a yellow powder, and the supernatant liquid was concentrated under reduced pressure (T < 30 °C) and crystallized from methanol to afford ethanone 4a (374 mg, 37%) as a white powder. A simple distilation of supernatant liquid provided N,N-dimethylformamide (0.07 mL, 35%). Alternatively, a ¹H NMR spectrum (CDCl₃) of crude residue A showed both DMF and ethanone 4a in the same proportion (from integration of signals at 8.2 ppm (1H, m) for DMF and at 4.43 ppm (2H, s) for **4a**).

4,5-Bis(2-bromophenyl)-5-hydroxy-2-isoxazoline (22a) was obtained as a mixture of diastereoisomers (a/b = 36/64) which showed the following selected data: ¹H NMR **a** (CDCl₃) δ 3.85 (1H, bs, O–H), 5.56 (1H, s, H-4); ¹H NMR **b** (CDCl₃) δ 3.79 (1H, bs, O–H), 5.71 (1H, s, H-4); ¹³C NMR **a** (CDCl₃) δ 62.6 (C-4), 107.8 (C-5), 151.1 (C-3); ¹³C NMR **b** (CDCl₃) δ 61.6 (C-4), 107.0 (C-5), 150.1 (C-3); FTIR (neat film, cm⁻¹): 3440 (O–H); EIMS (m/z, %) 399 (M + 2, 2), 397 (M⁺, 4), 395 (M – 2, 2), 379 (M–H₂O, 2), 318 (M – Br,⁷⁹ 7), 316 (M – Br,⁸¹ 7), 185 (100), 183 (99).

The same procedure on enaminone **18b** afforded the following products:

4,5-Bis(2-iodophenyl)-5-hydroxy-2-isoxazoline (22b) (61%) was obtained as a mixture of diastereoisomers (**a/b** = 22/78) which showed the following selected data: ¹H NMR **a** (CDCl₃) δ 3.19 (1H, bs, O–H), 5.44 (1H, s, H-4); ¹H NMR **b** (CDCl₃) δ 3.01 (1H, bs, O–H), 5.56 (1H, s, H-4); ¹³C NMR **a** (CDCl₃) δ 66.7 (C-4), 106.9 (C-5), 150.6 (C-3); ¹³C NMR **b** (CDCl₃) δ 67.2 (C-4), 105.2 (C-5), 149.4 (C-3); FTIR (neat film, cm⁻¹): 3435 (O–H); EIMS (*m*/*z*, %) 491 (M⁺, 6), 473 (M – H₂O, 4), 364 (M – I, 12), 231 (100).

1,2-Bis(2-iodophenyl)ethanone (4b) (31%).

The same procedure on enaminone **18c** afforded the following products: **4,5-Bis(2-bromo-4,5-dimethoxyphenyl)-5-hydroxy-2isoxazoline (22c)** (66%) was obtained as a mixture of diastereoisomers (**a/b** = 46/54) which showed the following selected data: ¹H NMR **a** (CDCl₃) δ 2.05 (1H, bs, O–H), 5.56 (1H, s, H-4); ¹H NMR **b** (CDCl₃) δ 2.61 (1H, bs, O–H), 5.34 (1H, s, H-4); ¹³C NMR **a** (CDCl₃) δ 62.7 (C-4), 106.6 (C-5), 151.5 (C-3); ¹³C NMR **b** (CDCl₃) δ 65.4 (C-4), 107.4 (C-5), 159.5 (C-3); FTIR (neat film, cm⁻¹): 3390 (O–H); EIMS (*m*/*z*, %) 499 (M–H₂O, 7), 497 (3), 438 (M – Br,⁷⁹ 4), 436 (M – Br,⁸¹ 4), 245 (100), 243 (96).

1,2-Bis(2-bromo-4,5-dimethoxyphenyl)ethanone (4c) (49%).

The same procedure on enaminone **18d** afforded the following products:

4,5-Bis(4,5-dimethoxy-2-iodophenyl)-5-hydroxy-2-isoxazoline (22d) (60%) was obtained as a mixture of diastereoisomers (**a/b** = 44/56) which showed the following selected data: ¹H NMR **a** (CDCl₃) δ 3.20 (1H, bs, O–H), 5.30 (1H, s, H-4); ¹H NMR **b** (CDCl₃) δ 3.49 (1H, bs, O–H), 5.39 (1H, s, H-4); ¹³C NMR **a** (CDCl₃) δ 67.3 (C-4), 105.2 (C-5), 149.6 (C-3); ¹³C NMR **b** (CDCl₃) δ 66.3 (C-4), 107.9 (C-5), 151.3 (C-3); FTIR (neat film, cm⁻¹): 3446 (O–H); EIMS (*m*/*z*, %) 593 (M – H₂O, 7), 484 (M – I, 4), 291 (100).

1,2-Bis(4,5-dimethoxy-2-iodophenyl)ethanone (4d) (35%). Heterocyclization Assisted by Ultrasounds.

4,5-Bis(2-bromophenyl)-5-hydroxy-2-isoxazoline (22a). Typical Procedure. NH₂OH·HCl (210 mg, 3.15 mmol) and Na₂CO₃ (170 mg, 1.6 mmol) were added to a stirred solution of enaminoketone **18a** (1.17 g, 2.86 mmol) in methanol (30 mL) and water (15 mL) at room temperature. The reaction mixture was acidified with glacial acetic acid up to pH 4–5 and sonicated for 16 h at 65 °C. After being cooled, the reaction mixture was basified to pH 8 with ammonium hydroxide solution and extracted with dichloromethane (4 × 30 mL). The organic extracts were dried over anhydrous sodium sulfate and evaporated in vacuo to give a yellow oil which was crystallized from 50% EtOAc/hexane, providing isoxazoline **22a** (80%) as a yellow powder (**a/b** diastereoisomers = 30/70).

By use of the same procedure, the following compounds were prepared:

4,5-Bis(2-iodophenyl)-5-hydroxy-2-isoxazoline (22b) (84%)(a/b diastereoisomers = 19/81).

4,5-Bis(2-bromo-4,5-dimethoxyphenyl)-5-hydroxy-2isoxazoline (22c) (78%) (a/b diastereoisomers = 43/57).

4,5-Bis(4,5-dimethoxy-2-iodophenyl)-5-hydroxy-2-isoxazoline (22d) (81%) (a/b diastereoisomers = 41/59)

Supporting Information Available: Tables of fractional coordinates, equivalent isotropic and anisotropic parameters, bond lengths and bond angles, complete computational results in the form of Cartesian coordinates with the computed total energies. This material is available free of charge via the Internet at http://pubs.acs.org

JO0002700